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A B S T R A C T
The development of drug resistance continues to be a dominant hindrance toward curative cancer treatment.
Overexpression of a wide-spectrum of ATP-dependent efflux pumps, and in particular of ABCB1 (P-glycoprotein
or MDR1) is a well-known resistance mechanism for a plethora of cancer chemotherapeutics including for ex-
ample taxenes, anthracyclines, Vinca alkaloids, and epipodopyllotoxins, demonstrated by a large array of pub-
lished papers, both in tumor cell lines and in a variety of tumors, including various solid tumors and hemato-
logical malignancies. Upon repeated or even single dose treatment of cultured tumor cells or tumors in vivo with
anti-tumor agents such as paclitaxel and doxorubicin, increased ABCB1 copy number has been demonstrated,
resulting from chromosomal amplification events at 7q11.2-21 locus, leading to marked P-glycoprotein over-
expression, and multidrug resistance (MDR). Clearly however, additional mechanisms such as single nucleotide
polymorphisms (SNPs) and epigenetic modifications have shown a role in the overexpression of ABCB1 and of
other MDR efflux pumps. However, notwithstanding the design of 4 generations of ABCB1 inhibitors and the
wealth of information on the biochemistry and substrate specificity of ABC transporters, translation of this vast
knowledge from the bench to the bedside has proven to be unexpectedly difficult.
Many studies show that upon repeated treatment schedules of cell cultures or tumors with taxenes and an-
thracyclines as well as other chemotherapeutic drugs, amplification, and/or overexpression of a series of genes
genomically surrounding the ABCB1 locus, is observed. Consequently, altered levels of other proteins may
contribute to the establishment of the MDR phenotype, and lead to poor clinical outcome. Thus, the genes
contained in this ABCB1 amplicon including ABCB4, SRI, DBF4, TMEM243, and RUNDC3B are overexpressed in
many cancers, and especially in MDR tumors, while TP53TG1 and DMTF1 are bona fide tumor suppressors. This
review describes the role of these genes in cancer and especially in the acquisition of MDR, elucidates possible
connections in transcriptional regulation (co-amplification/repression) of genes belonging to the same ABCB1
amplicon region, and delineates their novel emerging contributions to tumor biology and possible strategies to
overcome cancer MDR.
Introduction
The development of drug resistance limits the effectiveness of che-
motherapeutic drug treatment in cancer, with over 90% treatment
failure rate in metastatic tumors. Many mechanisms, either intrinsic or
acquired, operate to confer drug resistance (Goler-Baron and Assaraf,
2011; Gonen and Assaraf, 2012; Gottesman, 2002; Holohan et al., 2013;
Housman et al., 2014; Ifergan et al., 2005; Longley et al., 2006;
Wijdeven et al., 2016; Zhitomirsky and Assaraf, 2016). Poor drug so-
lubility and toxicity to normal tissues limit the doses of chemother-
apeutic drugs that can be administered to cancer patients, while phar-
macokinetic effects, i.e. absorption, distribution, metabolism and
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elimination, limit the actual amount of drug that reaches the tumor.
Furthermore, at the level of the tumor, several established mechanisms
confer resistance to one or more chemotherapeutic agents including
impaired drug uptake due to decreased expression and/or loss of drug
influx transporters, enhanced drug efflux, alterations in plasma mem-
brane lipid composition, inhibition of apoptosis, enhanced DNA da-
mage repair, cell cycle and/or checkpoint alterations, drug compart-
mentalization away from the drug target, increased drug metabolism
and inactivation, drug target alteration, and epithelial-mesenchymal
(EMT) transition (Bram et al., 2009; Debatin and Krammer, 2004; Fojo
and Bates, 2003; Goler-Baron et al., 2012; Gonen and Assaraf, 2012;
Holohan et al., 2013; Housman et al., 2014; Ifergan et al., 2005; Lowe
et al., 2004; Maier et al., 2005; Raz et al., 2014; Stark et al., 2011;
Zhitomirsky and Assaraf, 2016) (Fig. 1). Some of these mechanisms
confer resistance to single agents, thus allowing possible effective
treatment with alternative chemotherapeutic drugs, while other confers
resistance to multiple, structurally unrelated chemotherapeutic drugs
(i.e. multidrug resistance, MDR), thereby rendering the tumor re-
fractory to drug treatment, hence markedly decreasing cure rates.
Moreover, tumor heterogeneity is an important determinant in the
development of drug resistance (Alizadeh et al., 2015; Andor et al.,
2016; Lawrence et al., 2013; Swanton, 2012): both genetic and non-
genetic mechanisms contribute to the generation of different sub-
populations of cancer cells within individual tumors, and clonal selec-
tion upon treatment can account for positive selection of drug-resistant
tumor populations. In particular, the presence of cancer stem cells
(CSCs) in the tumor is a critical factor for the acquisition of chemore-
sistance. CSCs constitute a minor subpopulation of cells intrinsically
resistant to chemotherapeutic drugs, due to epigenetic mechanisms that
determine increased expression of anti-apoptotic proteins and of ATP-
binding cassette (ABC) transporters, which mediate multidrug efflux,
and their inherent quiescence (Al-Hajj et al., 2004; Dean, 2009;
Feuerhake et al., 2000; Lerner and Harrison, 1990; Peters et al., 1998;
Shibue and Weinberg, 2017; Zhou et al., 2001). Since the drug treat-
ment affects only the sensitive population, the drug-resistant cell sub-
population survives and eventually spreads, making the cancer treat-
ment ineffective.
MDR efflux pumps of the ABC superfamily of transporters
Among the mechanisms of drug resistance, the predominant one in
cancer cells and possibly the most studied one is the drug efflux by pro-
teins of a large superfamily of ATP-dependent efflux pumps, i.e. the ATP-
binding cassette (ABC) transporters (Li et al., 2016b). This superfamily is
composed of 48 genes and 3 pseudogenes (HUGO Gene Nomenclature
Committee, http://www.genenames.org/cgi-bin/genefamilies/set/417),
belonging to 7 subfamilies (ABCA through ABCG), mostly ATP-dependent
transporters of metabolites, xenobiotics and signaling molecules through
cell membranes against their concentration gradients (Dean, 2005;
Fletcher et al., 2010; Fletcher et al., 2016). ABC transporters belong to one
of the largest and more diffused superfamily, with representatives in all
phyla, from prokaryotes to humans (Wilkens, 2015). ABC transporters can
be grouped into exporters (which export lipids, sterols, drugs, and a large
variety of primary and secondary metabolites) and importers (which take
up a large variety of nutrients, biosynthetic precursors, trace metals and
vitamins); bacteria use both ABC importers and exporters, while all eu-
karyotic ABC pumps are exporters, except for ABCA4 (Quazi et al., 2012).
Structural organization of ABC transporters
Canonically, ABC transporters are organized in four domains, i.e.
two nucleotide-binding well conserved domains (NBD) or subunits and
two transmembrane domains (TBD) or subunits, that can be more
heterogeneous (Fig. 2). Prokaryotic ABC transporters are often as-
sembled from separate protein subunits, composed of two NBDs and
two TMDs, either identical (homodimeric) or different (heterodimeric);
most importers have additional substrate-binding domains or proteins,
which bind the substrate in the periplasm (Gram-negative bacteria) or
external space (Gram-positive bacteria and Archaea) and deliver it to
the TMDs. Eukaryotic exporters are composed of one rather large
polypeptide containing two NBDs and two TMDs (e.g., ABCB1), or
consist of two polypeptides, each of which contains an NBD and a TMD
as in the prokaryotic exporters (Biemans-Oldehinkel et al., 2006; ter
Beek et al., 2014).
The NBDs are ABC components, i.e. ATPase domains that bind and
hydrolyze ATP, about 200-amino acid long, with two subdomains, a
RecA-like domain and a α-helical domain (Fig. 2A). NBDs are char-
acterized by the presence of the following motifs: 1) An A-loop, with a
conserved aromatic residue (often a tyrosine), that serves to position
the ATP by stacking with the adenine ring; 2) the P-loop or Walker A
motif (GXXGXGK(S/T)), a phosphate-binding loop with a highly con-
served lysine residue, whose backbone amide nitrogens and the ε-amino
group form a network of interactions with β- and γ-phosphates of ATP;
3) the Walker B motif (ϕϕϕϕDE, where ϕ is a hydrophobic amino acid)
which coordinates the magnesium ion via the conserved aspartate re-
sidue, while the second acidic residue at the end (usually a glutamate
residue) is the general base that polarizes the attacking water molecule
(Oldham and Chen, 2011); 4) the D-loop (consensus motif: SALD); 5)
the H-loop (or switch region), with a highly conserved histidine that
interacts with the conserved aspartate from the D-loop, the glutamate
residue of the Walker B motif and with the γ-phosphate of the ATP, and
helps positioning of the attacking water, of the general base and of the
magnesium ion; 6) the Q-loop, containing eight residues with a con-
served N-terminal glutamine, located at the interface between the
RecA-like subdomain and the α-helical subdomain, in contact with the
TMDs; the glutamine residue can move in and out of the active site
during the ATP hydrolysis cycle, forming the active site upon Mg-ATP
binding and disrupting upon ATP hydrolysis; 7) the ABC signature motif
(or C motif, LSGGQ) is located at the α-helical subdomain, a char-
acteristic feature of the ABC superfamily, not present in other P-loop
Fig. 1. Mechanisms that confer drug resistance upon human cancer cells.
Left: pharmacokinetic factors, i.e. drug absorption, distribution, metabo-
lism and elimination (ADME), limit the effective concentration of the drug
that reach the cancer. Center and right: Drug influx and efflux limit the
amount of drug that enters the tumor cell; multiple documented me-
chanisms, such as drug inactivation, drug target alteration, drug com-
partmentalization, enhanced DNA damage repair, cell cycle/checkpoint
alterations, apoptosis inhibition and epigenetic alterations limit tumor cell
death; epithelial-to-mesenchymal transition and metastasis are also pos-
sible escape routes of tumor cells (Alizadeh et al., 2015; Gonen and
Assaraf, 2012; Holohan et al., 2013; Housman et al., 2014; Wijdeven et al.,
2016; Zhitomirsky and Assaraf, 2016).
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NTPases such as the F1-ATPase (Hanekop et al., 2006; Li et al., 2016b;
Smith et al., 2002; ter Beek et al., 2014; Verdon et al., 2003).
Two ATP binding sites are formed by the two NBDs of each ABC
transporters; however, it is yet unclear whether or not the hydrolysis of
two ATP molecules is needed for each transport cycle. In the bacterial
maltose transporter MalEFGK2 two functional ATP sites are needed,
while only one functional ATP site is needed in the histidine transporter
HisP2MQJ, and some ATP transporters have only a single ATPase site,
while the second one is degenerated (Davidson and Sharma, 1997;
Jones and George, 2013; Nikaido and Ames, 1999; Procko et al., 2009).
The two NBDs can assume a closed conformation if tightly packed to-
gether, or an open conformation if more distant. ATP hydrolysis can
take place only in the closed conformation; the release of ADP and
phosphate destabilizes the NBD dimer, the RecA-like and α-helical
domains move apart, the NBD dimer dissociates, and the movement can
be transmitted to the TMDs.
TMDs are more heterogeneous. In ABC exporters, however, TMDs
have a common structural fold, based on the presence of a six trans-
membrane helix-based core (Fig. 2B), which considerably stretches out
into the cytosol, where a short coupling helix protrudes from the TMD
and fits in a groove of NBD between the RecA-like and α-helical do-
mains, containing the Q-loop, allowing the transduction of the ATP-
dependent movement of NBD to TMD (Dawson and Locher, 2006;
Hollenstein et al., 2007). The transmembrane helices of the two TMDs
usually form a pore that can either be accessible from the cytoplasm
(inward facing) or from outside the cell (outward facing) (Figs. 2 and
3): according to the alternating-access model, alternation between these
conformations occurs during the catalytic cycle, to allow substrate
binding and its transport across the membrane, against its chemical
gradient (Ward et al., 2007).
Several catalytic mechanisms have been proposed for ABC trans-
porters (Higgins and Linton, 2004; Jones and George, 2014; Linton and
Higgins, 2007; Sauna et al., 2007; Senior et al., 1995). For eukaryotic
ABC exporters, the catalytic cycle has the following steps: substrate
binding to the inward face of TDMs, binding of two ATP molecules to
NBDs, dimerization of the NBDs, conformational change of TMDs from
inward facing to outward facing, ATP hydrolysis, release of substrate
from the outward face of TMDs and of ADP and phosphate from NBDs
and NBD dissociation (Wilkens, 2015). However, it is likely that not all
ATP transporters function based on the very same mechanisms (Locher,
2016): lipid transporters as PglK and ABCA1 have been proposed to
have only outwardly-facing conformations, and possibly a lateral access
mechanism (Perez et al., 2015; Qian et al., 2017). The substrate-binding
site is rather poorly defined in ABC exporters, and multiple and flexible
sites can be present, therefore making them multidrug transporters and
generating overlapping exporting function among them.
ABC transporters and MDR
Enhanced efflux of chemotherapeutic drugs by at least 15 ABC ex-
porters has been shown to mediate MDR in cancer cells (Fletcher et al.,
2016; Li et al., 2016b; Szakacs et al., 2006). The most important human
ABC transporter involved in drug disposition and in MDR is ABCB1
(also known as MDR1, P-glycoprotein, P-gp), while an important role is
recognized also for ABCG2 (Breast cancer resistance protein, BRCP) and
for ABCC1 (Multidrug Resistance Protein 1, MRP1), ABC exporters with
broad substrate and inhibitor specificity, and wide tissue and cellular
distribution, especially in physiological epithelial/endothelial barriers,
partially overlapping with those of ABCB1 (Fletcher et al., 2016; Mao
and Unadkat, 2015; Natarajan et al., 2012; Zhang et al., 2015).
ABCB1 (MDR1, P-glycoprotein, P-gp)
ABCB1 has been discovered more than 40 years ago (Juliano and
Ling, 1976). In humans, the ABCB1 and ABCB4 genes, originating from
an endoduplication event, are located adjacent to each other on the
long arm of chromosome 7 (7q21) and encode two similar proteins
(78% identity) (Callen et al., 1987; Chin et al., 1989). In rodents, a
further duplication gave rise to the genes ABCB1a and ABCB1b, with
largely overlapping substrate specificities.
ABCB1 structure and function
ABCB1 is expressed at low levels in most human and rodent tissues,
while high expression levels are present in the apical surface of epi-
thelial cells, such as intestine, liver bile ductile, kidney proximal tu-
bules, pancreatic ductules, adrenal gland, placenta, testis (blood-testis
barrier) and brain capillaries (blood-brain barrier), oriented towards
the lumen or the blood (Chin et al., 1989; Cordon-Cardo et al., 1990;
Cordon-Cardo et al., 1989; Fojo et al., 1987; Schinkel, 1999; Thiebaut
et al., 1987).
To characterize the function of ABCB1, knockout mice were gen-
erated harboring a disruption of the ABCB1a gene, the ABCB1b gene, or
both the ABCB1a and ABCB1b genes together (Schinkel et al., 1997;
Schinkel et al., 1994). These three mouse strains were healthy and
fertile, with no abnormalities in anatomy, lifespan and in many other
parameters, with respect to wild type mice under normal conditions;
however, they displayed drastic pharmacokinetic differences upon ad-
ministration of drugs, with marked reduction of the intestinal, hepa-
tobiliary and urinary excretion of drugs (Schinkel et al., 1997; Schinkel
et al., 1994; Smit et al., 1998; Sparreboom et al., 1997; van Asperen
et al., 1996; van Asperen et al., 1999). Altered pharmacokinetics and
increased accumulation of paclitaxel, doxorubicin and vinblastine, i.e.
some of the most important chemotherapeutic drugs, administered
Fig. 2. Structure of a Nucleotide Binding Domain (NBD) and a
Transmembrane Domain (TMD) of ABCB1 (PDB code: 4M2T). A. Structure
of NBD: domains and highly conserved sequence motifs are color-coded:
Green, α-helical domain; Gray, regulatory C-terminal domain; Red, A-
loop; Magenta, Walker A; Orange, Walker B; Blue, D-loop; Green, H-loop;
Cyan, ABC motif; Yellow, Q-loop. B: Structure of ABCB1 TMD dimer, view
along the two-fold symmetry axis from the inward side (the NBD domain is
not represented): the two TMDs of an ABC transporter are colored in blue
and orange. α-helices are numbered TMD1-12. (For interpretation of the
references to colour in this figure legend, the reader is referred to the web
version of this article.)
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against a number of cancers, was demonstrated in these mice
(Sparreboom et al., 1997; van Asperen et al., 1996; van Asperen et al.,
1999). In addition, ivermectin, loperamide, doxorubicin, digoxin, vin-
blastine, paclitaxel, erythromycin and many other drugs, which in wild
type mice (and in humans) do not accumulate in the brain and are not
neurotoxic, penetrate the blood-brain barrier and have serious neuro-
toxic effects in the CNS of ABCB1(-/-) mice (Schinkel et al., 1994;
Schinkel et al., 1996; Schinkel et al., 1995; Schuetz et al., 1998; van
Asperen et al., 1997).
Thus, both localization and characterization indicate an important
role of ABCB1 in the protection of the brain, the testis and of the fetus
from toxic xenobiotics. ABCB1 is responsible for the extrusion of xe-
nobiotics and metabolites into the gut lumen, into the bile and urine,
thus reducing their absorption, toxicity and bioavailability and hence
making a major contribution to their ADME (absorption, distribution,
metabolism and excretion). ABCB1 possibly plays a role in the transport
of endogenous molecules and metabolites (such as phospholipids, gly-
colipids, platelet-activating factors, amyloid β-peptides, and cytokines)
and in exporting hormones such as aldosterone and progesterone, from
the adrenal gland and the uterine epithelium (Sharom, 2008, 2011;
Silva et al., 2015).
Several crystal structures of eukaryotic ABCB1 proteins from mouse,
Cyanidioschyzon merolae and Caenorhabditis elegans have been reported
(Aller et al., 2009; Esser et al., 2017; Jin et al., 2012; Kodan et al., 2014;
Li et al., 2014; Szewczyk et al., 2015; Verhalen et al., 2017; Ward et al.,
2013; Wen et al., 2013), and showed that the overall structure of
ABCB1 is similar to that of other ABC transporters (Fig. 3). Since ABCB1
is expressed as one gene product containing both halves, similar but not
identical, its structure is intrinsically asymmetric (Wen et al., 2013).
Structures of mouse ABCB1a (87% identical to human ABCB1) in the
apo-form, of mutant forms and in the presence of rationally designed
ligands yielded insight on the “polyspecificity” of ABCB1 in substrate
interactions, on mechanism of ligand entry and on atomistic models of
ATP-coupled transport (Fig. 4). All structures belong to a wide range of
inward-facing conformations, with highly flexible TMDs and various
distances between the two NBDs, which can determine opening and
closing motion of the ABC exporter and thereby a number of possible
binding sites due to the exposure of several flexible hydrophobic sur-
faces in the vicinity of the membrane (Esser et al., 2017; Szewczyk
et al., 2015; Verhalen et al., 2017; Ward et al., 2013). A recent work by
McHaurab and colleagues used double electron–electron resonance and
molecular dynamics simulations to model ABCB1 in the outward-facing
conformation and to model energy-dependent movement and substrate
efflux (Fig. 4). In this model, most ABCB1 molecules in the cell are
inward-facing, with dissociated and fully ATP-bound NBDs (Fig. 4, step
1), ready to bind the substrate with its high-affinity substrate pocket
exposed to the cytoplasmic leaflet of the membrane (Fig. 4, step 2);
drug extrusion requires a two-stage hydrolysis (Fig. 4, steps 3 and 4),
and substrate release outside the cell by outwardly-facing ABCB1, a
conformation with lower affinity for the substrate (Verhalen et al.,
2017).
ABCB1 expression in cancers and MDR
In various cancer cell lines of distinct tissue lineage, ABCB1 ex-
pression increases upon repeated drug treatment cycles with various
chemotherapeutic drugs, rendering them MDR (Juliano and Ling, 1976;
Ueda et al., 1987a; Assaraf et al., 1989a, 1989b). In addition, many
early studies showed high overexpression of ABCB1 in colon, kidney,
ovary, adrenocortical and hepatocellular tumors (Bourhis et al., 1989;
Fojo et al., 1987; Goldstein et al., 1989; Pirker et al., 1989). Direct
association between ABCB1 expression levels, drug resistance and poor
prognosis have been found in acute myelogenous leukemia (AML)
(Broxterman et al., 1999; Dorr et al., 2001; Grogan et al., 1993; Han
et al., 2000; Leith et al., 1999; Michieli et al., 1999; van der Kolk et al.,
2000; Zhou et al., 1995), breast cancer (Burger et al., 2003; Dexter
Fig. 4. Mechanism of action of ABCB1. Top-left: inward-facing (IF), ATP-bound ABCB1
with non-dimerized NBDs; top-right: upon substrate binding, NBDs dimerize; bottom-
right: hydrolysis of the first ATP occurs, and a doubly occluded (OO) transition state is
formed; bottom-left: after hydrolysis of the second ATP, an outward-facing (OF) transition
state is formed, and release of the substrate outside the cell occurs (Verhalen et al., 2017).
Fig. 3. Structures of ABC exporters in outward-facing and inward-facing
conformations. Left: structure of Staphylococcus aureus SAV1866 in com-
plex with ADP (PDB code: 2HYD), in outward-facing conformation. Right:
Structure of mouse ABCB1 (MDR1) in inward-facing conformation, in
complex with two molecules of an analog of dendroamide-A (PDB code:
4M2T) (Dawson and Locher, 2006; Li et al., 2014).
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et al., 1998; Kao et al., 2001; Nooter et al., 1997; Sun et al., 2000; Trock
et al., 1997; Vecchio et al., 1997), osteosarcoma (Chan et al., 1997),
bladder cancer (Clifford et al., 1996; Nakagawa et al., 1997; Park et al.,
1994; Tada et al., 2002), ovarian cancer (van der Zee et al., 1995),
central nervous system (Abe et al., 1998; Perri et al., 2001) and other
tumors and diseases.
In the Guidance Compliance Regulatory Information for the eva-
luation of drug interactions (https://www.fda.gov/downloads/Drugs/
GuidanceComplianceRegulatoryInformation/Guidances/ucm292362.
pdf), the US Food and Drug Administration (FDA) recommends that all
investigational drugs should be evaluated in vitro to determine whether
or not they are transport substrates of ABCB1 (P-glycoprotein) or
ABCG2 (BCRP); the International Transporter Consortium recommends
in vitro analysis of interaction with ABCB1 as a major bottleneck for
filing a new drug application (International Transporter et al., 2010).
ABCB1 mutations and polymorphism
In the last years, a number of mutations and polymorphisms in the
human ABCB1 gene have been described, although sometimes with
conflicting results (Schwab et al., 2003; Wolking et al., 2015). The NCBI
dbSNP single nucleotide polymorphisms database currently (September
11th, 2017) lists 24289 nucleotide variants, including 1563 coding
sequence variants (639 missense and 924 synonymous variants).
Among the identified single nucleotide polymorphisms (SNPs), the
dbSNP database counts only 1 pathogenic SNP, i.e. c.554G > T,
yielding the G185V mutation (Choi et al., 1988; Safa et al., 1990). In
addition, at least 14 SNPs, occurring only at low allele frequencies of
<0.01, are reported to be associated with alterations in ABCB1 func-
tions (Wolf et al., 2011), concerning pharmacokinetics, treatment re-
sponse and drug-related toxicity; the analysis of the literature show that
no conclusive results are available (Wolking et al., 2015).
Epigenetic regulation of ABCB1 expression in drug response
Deregulation of epigenetic programs, in terms of DNA methylation
and post-transcriptional regulation of histone proteins, cooperates with
genetic alterations towards the establishment and progression of cancer
as well as the development of the classical MDR phenotype mediated by
ABCB1 (Baker et al., 2005; Chen et al., 2005; Scotto, 2003). The binding
of specific transcription factors to their DNA-response elements located
in ‘distal’ and ‘proximal’ promoter regions of the ABCB1 gene (Ueda
et al., 1987b), and the methylation/demethylation status of this
genomic locus, determine the repression or transactivation of ABCB1
expression, associated with survival and treatment response (Arrigoni
et al., 2016; Dejeux et al., 2010; Mencalha et al., 2013; Reed et al.,
2010). In AML for example, an inverse correlation between methylation
and ABCB1 expression in clinical samples has been described; the hy-
pomethylated status of ABCB1 promoter region was proposed as a ne-
cessary condition for ABCB1 gene overexpression and for the estab-
lishment of P-glycoprotein-mediated MDR in AML patients (Nakayama
et al., 1998). In bladder cancer as well, the degree of methylation in the
ABCB1 promoter region appears to be closely associated with ABCB1
gene expression and the emergence of the MDR phenotype (Tada et al.,
2000). In breast cancer, the acquisition of drug resistance appears to be
related to the methylation of the ABCB1 downstream promoter ac-
companied by a regional genomic amplification of a locus in chromo-
some 7 containing the ABCB1 gene and its ABCB4 neighbor gene (Reed
et al., 2008).
Recently, also the histone methylation and acetylation, occurring on
lysine residues within histone tails, are emerging as relevant players for
the epigenetic regulation of ABCB1 gene expression and chemotherapy
drug response (Henrique et al., 2013). Huo et al., evidenced that
transcriptional activation of ABCB1 gene expression is accompanied by
increased methylation on lysine 4 of histone H3 (H3K4), and that the
histone methyltransferase MLL1 is involved in this regulation. In this
respect, knockdown of MLL1 decreased the constitutive expression of
ABCB1, increased cellular retention of ABCB1 substrates, and sensitized
cancer cells to chemotherapeutic agents (Huo et al., 2010). An induc-
tion of H3K4 methylation within the coding regions of the ABCB1 gene
was also evidenced after treatment with the histone deacetylase
(HDAC) inhibitor Trichostatin A (TSA), resulting in upregulation of
ABCB1 (Baker et al., 2005; Jin and Scotto, 1998). Interestingly, it was
also shown that TSA treatment induced an increase in ABCB1 expres-
sion in drug-sensitive small cell lung carcinoma (SCLC) cells, but
strongly decreased its expression in drug-resistant cells through a
transcriptional mechanism, independently from promoter methylation
(El-Khoury et al., 2007). Moreover, in colon and pancreatic cancer cell
lines, it was demonstrated that the increase in ABCB1mRNA expression
observed after TSA treatment is not associated with an active P-gp
protein expression, suggesting that well tolerated HDAC inhibitors may
represent a potential therapeutic avenue to potentiate the effects of
anti-tumor drugs that are P-glycoprotein substrates (Balaguer et al.,
2012). In T-cell leukemia, the transcriptional control of ABCB1 ex-
pression is achieved by two molecular mechanisms: when densely
methylated, ABCB1 is transcriptionally silent via a mechanism that is
TSA independent. TSA induced significant acetylation of histones H3
and H4 but did not activate transcription, whereas 5-azacytidine, in-
ducing DNA demethylation, lead to partial relief of transcriptional re-
pression. ABCB1 expression was significantly increased following the
combination of 5-azacytidine and TSA treatments suggesting that, upon
demethylation, activation of ABCB1 is mediated by HDAC (El-Osta
et al., 2002). Of note, the use of depsipeptide, an HDAC inhibitor, in
combination with retinoic acid (RA) treatment, in Acute Promyelocytic
Leukemia (APL) cells, prior to doxorubicin treatment, prevents doxor-
ubicin-induced apoptosis in NB4 APL cells, by inducing the ABCB1 gene
and ABCB1 expression, partially through CCAAT box-associated histone
acetylation (Tabe et al., 2006). On the contrary, combined treatment of
depsipeptide and RA following doxorubicin treatment, lead to en-
hanced doxorubicin-induced apoptosis. These results underline the
critical importance of modulation of ABCB1 expression by the use of
epigenetics modulating drugs, and indicate that this is a critical point to
take into consideration for the future design of clinical trials that
combine epigenetics modulators and chemotherapeutic agents.
Post-transcriptional regulation of ABCB1 expression by microRNAs in drug
response
miRNAs are small (≈22 nucleotides long) noncoding RNAs which
are evolutionary conserved and play a key role in the regulation of gene
expression; miRNAs are significantly deregulated in cancer, and each
cancer phenotype is defined and characterized by a unique miRNA
signature, highlighting miRNAs as relevant molecules for cancer diag-
nostics and possible therapeutic interventions (Blandino et al., 2014).
miRNAs can act by targeting a spectrum of distinct players, involved in
the establishment of cancer MDR (Zhang and Wang, 2017). Of note,
since many drugs need the expression of specific genes to exert their
antineoplastic activity, miRNAs which affect the post-transcriptional
regulation of pharmacogenomics-related genes, such as those re-
sponsible for drug metabolism or transport as well as those directly
targeted by the drugs, are also emerging as potent regulators of drug
efficacy (Rukov and Shomron, 2011). Several miRNAs are involved in
different regulatory pathways that confer chemoresistance to cancer
cells, as the ID4-miR-9*-SOX2-ABCC3/ABCC6 pathway which imparts
stemness potential and chemoresistance in glioma cells (Jeon et al.,
2011), and the miR27b-CCNG1-p53-miR-508-5p axis which regulates
MDR in gastric cancer (Shang et al., 2016).
The identification of the expression levels of miRNAs targeting
genes involved in the binding or in the transport of chemotherapeutic
drugs may be extremely useful to identify the possible acquisition of
drug resistance during cancer treatment (Yamamoto et al., 2011). For
example, Pan et al. found that miR-328, which targets the ABCG2 gene,
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encoding for a MDR efflux transporter of the ABC superfamily, may
affect the transport of the anticancer drug mitoxantrone (MX) across the
plasma membrane and the sensitivity of MCF-7 breast cancer cells to
this anthracycline drug (Pan et al., 2009). Also miR-345 and miR-7,
targeting ABCC1 gene, which encodes for the human multidrug re-
sistance-associated protein 1 (MRP1), were associated with acquired
resistance of MCF-7 breast cancer cells to cisplatin (Pogribny et al.,
2010).
Moreover, different miRNAs were described with a functional role
in the regulation of the expression and activity of ABCB1, the founding
member of the ABC superfamily of multidrug efflux transporters that is
a dominant pump responsible for MDR (Garofalo and Croce, 2013; Li
et al., 2016b; Livney and Assaraf, 2013; Wijdeven et al., 2016). As
described above, the plasma membrane overexpression of ABCB1 in
cancer cells leads to an increased drug efflux and impairs the
achievement of an intracellular cytotoxic drug concentration. Of note,
various miRNAs targeting this ABC superfamily member were described
to be involved in the regulation of drug efflux activity of this trans-
porter as well as in drug response (Geretto et al., 2017; Lopes-Rodrigues
et al., 2014). It has been shown that 3′-UTR variants of ABCB1 with
shortened length may be synthesized during the acquisition of drug
resistance and this may lead to the loss of miRNA binding sites and
hence alleviating this miRNA-based repression of ABCB1 expression
(Bruhn et al., 2016). However, altered levels of miRNAs affecting
ABCB1 expression were also recently described. For example, in human
intestinal epithelial cells miR-145 negatively regulates the expression
and function of ABCB1 through direct interaction with its mRNA 3′-
UTR (Ikemura et al., 2013), while in ovarian cancer the development of
cisplatin resistance was related to the up-regulation of miR-130a, re-
sulting in ABCB1-mediated MDR (Li et al., 2015; Yang et al., 2012). By
targeting ABCB1, miR-873 and miR-595 also contribute to the regula-
tion of drug resistance and the activity of cisplatin in inhibiting tumor
growth in ovarian cancer (Tian et al., 2016; Wu et al., 2016). Inter-
estingly, miR-27a and miR-451 induce the activation of ABCB1 ex-
pression and their modulation with antagomirs enhances the sensitivity
of ovarian cancer cells via enhanced intracellular accumulation of
doxorubicin (Zhu et al., 2008). In contrast, in colorectal cancer, re-
storation of miR-451 decreases ABCB1 expression and results in sensi-
tization to irinotecan (Bitarte et al., 2011); whereas, up-regulation of
miR-27a in hepatocellular carcinoma cells decreased the ABCB1 ex-
pression via FZD7/β-catenin signaling pathway, enhancing the sensi-
tivity of these cells to 5-fluorouracil resulting in 5-fluorouracil-induced
apoptosis (Chen et al., 2013b). Moreover, in breast cancer cells as well,
miR-451 was reported to mediate down-regulation of ABCB1 gene ex-
pression, resulting in increased sensitivity of tMCF-7 breast cancer cells
to doxorubicin (Kovalchuk et al., 2008). In hepatocellular carcinoma
cells, a novel role for miR-491-3p was identified resulting in ABCB1-
mediated MDR, suggesting the potential application of miR-491-3p as a
therapeutic strategy for repression of P-glycoprotein-dependent MDR
tumors (Zhao et al., 2017). In gastric cancer, the overexpression of miR-
508-5p, targeting the 3′-UTR of ABCB1, was sufficient to reverse MDR
in cancer cells to multiple chemotherapeutic drugs, both in vitro and in
vivo, and, interestingly, miR-508-5p might act as a prognostic factor for
overall survival in this tumor (Shang et al., 2014). In neuroblastoma
cells, it was shown that epigenetic silencing of miR-137 in doxorubicin-
resistant cells contributes to overexpression of the constitutive an-
drostane receptor (CAR) and, in turn, ABCB1, and that treatment with
the 5-azacytidine, a methylation inhibitor, increased miR-137 expres-
sion and sensitized doxorubicin-resistant neuroblastoma cells to this
anthracycline (Takwi et al., 2014). Moreover, the hyper-methylation of
the promoter region of miR-129-5p is recently gaining relevance in the
development of drug resistance in gastric cancer cells and this miRNA,
by targeting MDR-related ABC transporters as ABCB1, was proposed as
a potential therapeutic target to enhance drug sensitivity of gastric
cancers (Wu et al., 2014). In gastric cancer, it was also evidenced that
miR-129 was able to reverse cisplatin-resistance through repression of
ABCB1 gene expression and activation of the caspase-mediated intrinsic
apoptotic pathway (Lu et al., 2017). Of note, the nanoparticles-medi-
ated co-delivery of miR-129-5p and doxorubicin significantly increased
miR-129-5p expression in doxorubicin-resistant MCF-7 breast cancer
cells, which effectively overcame MDR achieving a 100-fold increase in
ABCB1 gene expression, thereby increasing intracellular drug accu-
mulation and cytotoxicity in this tumor cell line model (Yi et al., 2016).
This synergistic therapeutic option was also recently reported for miR-
375 in hepatocellular carcinoma (Fan et al., 2017). Moreover, in breast
cancer it was further reported that the overexpression of miR-298 as
well results in down-regulation of ABCB1 gene expression, increasing
nuclear accumulation of doxorubicin and cytotoxicity in doxorubicin-
resistant cells (Bao et al., 2012). In mouse leukemia cells it was reported
that the restored expression of miR-381 or miR-495 in doxorubicin-
resistant K562 cells correlates with a decreased ABCB1 gene expression
and with an increased drug uptake by these cells (Xu et al., 2013). More
recently, in the same cellular system, restoration of miR-9 expression
was also able to reverse cancer cell drug resistance in vitro and sensi-
tized tumors to chemotherapy in vivo by targeted repression of ABCB1
gene expression (Li et al., 2017). In addition, in gallbladder cancer,
miR-218-5p enhanced sensitivity of gemcitabine by abolishing PRKCE-
induced up-regulation of ABCB1 (Wang et al., 2017). Table 1 shows
miRNAs acting on ABCB1 in MDR (vs. non-MDR) tumors.
Transport substrates of ABCB1
ABCB1 is able to bind and extrude out of cells a plethora of che-
mically, structurally and pharmaceutically distinct compounds in-
cluding drugs used as anti-cancer chemotherapeutics, inflammation,
immunosuppression, infection, allergy, hypertension, and arrhythmia
(Table 2); more than one thousand compounds have been described as
ABCB1 substrates (Didziapetris et al., 2003). The high flexibility, fuz-
ziness and complexity of drug substrate binding sites of ABCB1 (Esser
et al., 2017; Szewczyk et al., 2015; Verhalen et al., 2017; Ward et al.,
2013) explain the wide number of drug classes of these ABCB1 sub-
strates, which include small molecules, as cations, amino acids and
carbohydrates, larger molecules, as chemotherapeutic drugs, iono-
phores, fluorescent dyes and steroids and larger molecules such as
peptides, polysaccharides and proteins (Borgnia et al., 1996;
Didziapetris et al., 2003; Eytan et al., 1994; Sharom, 2011; Silva et al.,
2015; Zhou, 2008). Many of these substrates are relatively hydrophobic
and weakly amphipathic, typically contain aromatic rings and a posi-
tively charged nitrogen, and often their binding occurs with KD values
of 10 μM–1 mM (Morrissey et al., 2012). This substrate “poly-
specificity” is crucial for ABCB1 to exert its role as a xenobiotics efflux
pump, able to protect cells from a high number of cytotoxicants. In
addition, substrates binding to ABCB1 partially overlap to those bound
by other ABC transporters, such as ABCC1, ABCC2 and ABCG2, and by
cytochrome P450 3A enzymes, in particular CYP3A4: a coordinate in-
terplay between these proteins can operate to protect cells as a barrier
in the bioavailability of drugs, especially when orally administered
(Cascorbi, 2006; Cummins et al., 2002; Kim et al., 1999).
ABCB1 transport inhibitors
The induction of ABCB1 upon exposure to cancer chemother-
apeutics is an important cause of MDR; conversely, inhibition of ABCB1
transport is one the most studied clinical strategies to counteract MDR,
with the aim to interfere with chemotherapeutic drug efflux, thereby
increasing their accumulation and hence their cytotoxic effect in cancer
cells. Mechanistically, ABCB1 inhibitors may exert their activity by
binding and blocking the substrate binding site of the transporter, ei-
ther in competitive, non-competitive or allosteric fashion, by interfering
with ATP hydrolysis, by binding the transporter in site independent of
the drug binding site which allosterically alters the intact structure and
function of ABCB1, or by altering the integrity and functionality of cell
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Table 1
miRNA acting on ABCB1 in MDR (vs. non-MDR) cancers.
miRNA Direct expression ABCB1 target Effect on Cancer
expression drug resistance
miR-9 ↓ ABCB1 ↑ ↑ Adriamycin MDR chronic myelogenous leukemia vs. non-MDR
miR-27a ↑ ? ↑ ↑ Doxorubicin, vinblastine MDR ovarian cancer vs. non-MDR
↓ FZD7/β-catenin ↑ ↑ 5-fluorouracil MDR hepatocellular carcinoma vs. non-MDR
miR-129 ↓ ABCB1 ↑ ↑ Cisplatin MDR gastric cancer vs. non-MDR
miR-129-5p ↓ ABCB1 ↑ ↑ Vincristine, 5-fluorouracil, cisplatin MDR gastric cancer vs. non-MDR
↓ ABCB1, CDK6 ↑ ↑ Doxorubicin MDR breast cancer vs. non-MDR
miR-130a ↓ ABCB1 ↑ ↑ Cisplatin MDR ovarian cancer vs. non-MDR
miR-137 ↓ CAR ↑ ↑ Doxorubicin MDR neuroblastoma vs. non-MDR
miR-145 ↓ ABCB1 ↑ Intestinal epithelial cells vs. ischemia-reperfusion
cells
miR-218-5p ↓ PRKCE ↑ ↑ Gemcitabine Gallbladder cancer vs. non cancer
miR-298 ↓ ABCB1 ↑ ↑ Doxorubicin MDR breast cancer vs. non-MDR
miR-375 ↓ ABCB1, AEG1, YAP1,
ATG7
↑ ↑ Doxorubicin MDR hepatocellular carcinoma vs. non-MDR
miR-381 ↓ ABCB1 ↑ ↑ Doxorubicin MDR chronic myelogenous leukemia vs. non-MDR
miR-451 ↑ ? ↑ ↑ Doxorubicin MDR ovarian cancer vs. non-MDR
↓ COX2/Wnt ↑ ↑ Irinotecan MDR colonspheres vs. non-MDR
↓ ABCB1 ↑ ↑ Doxorubicin MDR breast cancer vs. non-MDR
miR-491-3p ↓ ABCB1, Sp3 ↑ ↑ Doxorubicin, vinblastine MDR hepatocellular carcinoma vs. non-MDR
miR-495 ↓ ABCB1 ↑ ↑ Doxorubicin MDR chronic myelogenous leukemia vs. non-MDR
miR-508-5p ↓ ABCB1, ZNRD1 ↑ ↑ Adriamycin, Vincristine, 5-fluorouracil,
cisplatin
MDR gastric cancer vs. non-MDR
miR-595 ↓ ABCB1 ↑ ↑ Cisplatin MDR ovarian cancer vs. non-MDR
miR-873 ↓ ABCB1 ↑ ↑ Cisplatin MDR ovarian cancer vs. non-MDR
Table 2
Classes of ABCB1 substrates.
Data from: Didziapetris et al. (2003), Sharom (2011), Silva et al. (2015), Zhou (2008).
Classes of ABCB1 substrates
Substrate class Examples
Anti-arrhythmics Digoxin, quinidine, verapamil.
Antibiotics (antimicrobial drugs) Clarithromycin, doxycycline, erythromycin, gramicidin A, grepafloxacin, itraconazole, ketoconazole, levofloxacin, rifampicin,
sparfloxacin, tetracycline, valinomycin.
Anticancer chemotherapeutic drugs Alkylating agents: chlorambucil, cisplatin
Antibiotics: actinomycines (actinomycin D), anthracyclines (daunorubicin, doxorubicin), mitoxantrone, mytomicin C.
Antimetabolites: cytarabine, 5-fluorouracil, hydroxyurea, methotrexate.
Camptothecins: irinotecan, topotecan.
Epidermal growth factor receptor inhibitors: erlotinib, gefitinib
Epipodophyllotoxins: etoposide, teniposide
Taxanes: docetaxel, paclitaxel.
Tyrosine kinase inhibitors: imatinib, nilotinib
Vinca alkaloids: vinblastine, vincristine
Others: bisantrene, tamoxifen.
Anticonvulsants and anti-epileptics Carbamazepine, phenobarbital, phenytoin, topiramate.
Antidepressants Amitriptyline, doxepin, nortriptyline.
Anti-diarrheal drugs Loperamide (opioid), octreotide
Antiemetics Domperidone, ondansetron.
Antigout drugs Colchicine
Antihelmintics Ivermectin
Antihistamine Fexofenadine, terfenadine.
Anti-HIV Amprenavir, indinavir, nelfinavir, ritonavir, saquinavir.
Antihypertensives Celiprolol, debrisoquine, losartan, prazosin, reserpine, talinolol.
Calcium channel blockers Azidopine, diltiazem, nicardipine nifedipine, verapamil.
Calmodulin antagonists trans-flupentixol, trifluoperazine.
Cardiac glycosides Digitoxin, digoxin.
Cyclic peptides Beauvericin, valspodar (PSC-833).
Fluorescent dyes Calcein AM, Hoechst 33342, Rhodamine 123.
Histamine H2-receptor antagonists Cimetidine, ranitidine
Hypocholesterolizing drugs Lovastatin, simvastatin
Immunosuppressive agents Cyclosporin A, sirolimus, tacrolimus, valspodar (PSC-833)
Linear peptides ALLN (Acetyl-leucyl-leucyl-norleucine), leupeptin, pepstatin A
Neuromuscular blocking agents Vecuronium
Natural products Curcumin, Flavonoids.
Neuroleptics Chlorpromazine, phenothiazine
Pesticides Endosulfan, methylparathion, paraquat.
Steroid hormones Aldosterone, corticosterone, cortisol, dexamethasone, estradiol, methylprednisolone.
Others Amino acids, bilirubin, carbohydrates, cations, polysaccharides
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membrane lipids, or by altering plasma membrane fluidity (Drori et al.,
1995; Shapiro and Ling, 1997; Silva et al., 2015; Varma et al., 2003).
Classification into four generations of ABCB1 inhibitors according to
their potency, selectivity and drug–drug interaction potential (Palmeira
et al., 2012a), rather than to their chronology of discovery and char-
acterization, is useful (Table 3). The first generation of ABCB1 transport
inhibitors comprises classical inhibitors such as the founding member
verapamil as well as cyclosporine A and all compounds which were
previously described as having other therapeutic applications. The first
identified ABCB1 transport inhibitor has been the calcium channel
blocker verapamil, able to increase the intracellular accumulation of
chemotherapeutic drugs as doxorubicin, vincristine and vinblastine by
competing with these drugs (Miller et al., 1991; Tsuruo et al., 1981).
Verapamil, as many other of first-generation ABCB1 substrate, and
presumably acts by competing for efflux with other ABCB1 substrates
(Varma et al., 2003; Yusa and Tsuruo, 1989). Verapamil sensitizes
cancer cells to several anticancer drugs, such as doxorubicin, increasing
their cytotoxic activity (Futscher et al., 1996); many clinical studies on
the use of verapamil, alone and in combination regimens, against var-
ious cancers and other diseases have been carried out, and some are still
ongoing (https://clinicaltrials.gov/). A number of “already-in-clinical-
use” ABCB1 inhibitors have been discovered, belonging to several
classes, such as calcium channels blockers (e.g., verapamil), anti-ma-
larial drugs (e.g., quinine), immunosuppressants (e.g., cyclosporine A),
anesthetics (e.g., chloroform), antibiotics (e.g., erythromycin, and cef-
triaxone), antifungal drugs (e.g., ketoconazole), antivirals (e.g., nelfi-
navir, and saquinavir), CNS stimulators or anti-depressants (e.g., caf-
feine, nicotine, and chlorpromazine), as well as steroids (e.g., cortisol,
and progesterone). In addition, some ABCB1 transport inhibitors are
themselves anticancer drugs, such as tamoxifen, and tyrosine kinase
inhibitors as erlotinib and lapatinib (Table 3) (Palmeira et al., 2012a;
Sharom, 2011; Silva et al., 2015; Zhou, 2008). Often, the clinical use of
these ABCB1 inhibitors is hampered by their intrinsic toxicity, because
high concentrations of these drugs are needed to inhibit ABCB1 efflux
Table 3
Classes of ABCB1 inhibitors.
Data from Palmeira et al. (2012a), Silva et al. (2015).
Classes of ABCB1 inhibitors
Inhibitor class Examples
First generation
Analgesics Meperidine, pentazocine
Anesthetic drugs Benzyl alcohol, chloroform, diethyl ether, propofol
Antibiotics Azithromycin, bafilomycin, brefeldin A, cefoperazone, ceftriaxone, clarithromycin, erythromycin, nigericin, salinomycin, valinomycin
Anticancer drugs Antiandrogen; bicalutamide, mitotane
Estrogen receptor antagonists: tamoxifen
Farnesyl trasferase inhibitors: lonafarnib, tipifarnib
Tyrosine kinase inhibitors: erlotinib, gefitinib, lapatinib
Antifungal drugs Aureobasidin A, dihydroptychantol A, econazole, itraconazole, ketoconazole
Antihistaminic drugs Astemizole, azelastine, benzquinamide, terfenadine, tesmilifene
Anti-inflammatory drugs Zomepirac, indomethacin, SC236, curcumin, ibuprofen, NS-398
Antidepressants Amoxapine, loxapine, sertraline, paroxetine, fluoxetine
Antiprotozoal drugs Hycanthone, metronidazole, monensin, quinine
Antiviral drugs Concanamycin A, nelfinavir, ritonavir, saquinavir
Anxiolytics Midazolam
Cardiac drugs Antiarrhythmics: amiodarone, propafenone, quinidine
Calcium channel blockers: amiodarone, bepridil, deverapamil, diltiazem, emopamil, felodipine, isradipine, lomerizine, mibefradil, nicardipine,
nifedipine, niguldipine, nimodipine, nitrendipine, propaphenone, quinidine, tetrandrine, verapamil.
Antiplatelet drug: dipyridamole
Antihypertensives: carvedilol, doxazosin, prazosin, reserpine.
CNS stimulators Amoxapine, caffeine, cotinine, loxapine, nicotine, pentoxifylline, sertraline
CNS depressants Chloropromazine, trans-flupentixol, haloperidol, perospirone, perphenazine, prochloropromazine, trifluoperazine
Cholesterol-lowering drugs Atorvastatin,
Immunosuppressant drugs Cyclosporin A, tacrolimus, sirolimus
Phosphodiesterase inhibitors Vardenafil
Steroid hormones Cortisol, medroxiprogesterone, methylprednisolone, mifepristone, progesterone, SB4723, SB4769, tirilazad, U-74389F
Others Bromocriptine, disulfiram, methadone, tetrabenazine
Second generation BIBW22BS, biricodar (VX 710), CGP 42700, cinchonine, dexverapamil, dexniguldipine, dofequidar (MS-209), hydro-cinchonine, KR-30031,
MM36, PAK-104P, quinine homodimer Q2, RO44-5912, S9788, SB-RA-31012 (tRA96023), stipiamide homodimer, timcodar (VX-853),
toremifene, valspodar (PSC 833), WK-X-34
Third generation Annamycin, CBT-1, DP7, elacridar (GF120918), laniquidar (R101933), mitotane, ontogen (OC144093), PGP-4008, tariquidar (XR9576),
zosuquidar (LY335979),
Fourth generation
Natural products Alkaloids: ellipticine, pervilleine F
Cannabinoids: cannabidiol
Coumarins: cnidiadin, conferone, DCK, praeruptorin A, rivulobirin A
Diterpenes: euphodendroidin D, jolkinol B, pepluanin A, portlanquinol
Flavonoids: baicalein heptamethoxyflavone, nobiletin, quercetin, sinensetin, tangeretin
Ginsenosides: 20S-ginsenoside
Lignans: nirtetralin, schisandrin A, silibinin
Polyenes: pentadeca-(8,13)-dien-11-yn-2-one
Sesquiterpenes: dihydro-β-agarofuransesquiterpenes
Taccalonolides: taccalonolides A
Triterpenes: oleanolic acid, sipholenol A, sipholenone E, uvaol
Peptidomimetics Peptide 15, reversin 121, reversin 205, XR9051
Surfactants and Lipids Cremophor EL, Nonidet P40 Pluronic P85, poly(ethylene glycol)-300 (PEG-300), Tween-20, Triton X-100,
Dual ligands Dual inhibitors of ABCB1 and tumor cell growth (e.g.: aminated thioxanthones)
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activity, given their low affinity for ABCB1. Further, since many first-
generation ABCB1 inhibitors are also substrates of other transporters
and/or enzymes, pharmacokinetic interactions are complex and some-
times unpredictable (Ambudkar et al., 1999).
Second-generation ABCB1 transport inhibitors were designed from
compounds with another recognized activity, but which were subjected
to structural modifications in order to decrease their principal ther-
apeutic activity and to enhance ABCB1 inhibitory activity, in order to
achieve decreased toxicity and higher potency (Kathawala et al., 2015;
Palmeira et al., 2012a; Silva et al., 2015). These compounds include
derivatives of anticancer, cardiovascular and immunosuppressive
agents (Table 2). For example, valspodar (PSC-833) is a non-im-
munosuppressive derivative of cyclosporine A; although it is 5- to 20-
fold more potent than its parent compound, and also exhibited pro-
mising pre-clinical results, its administration in combination with an-
ticancer drugs inhibits the metabolism and extrusion of such cytotoxic
agents, thus leading to unacceptable toxicity which requires che-
motherapy dose reduction (Advani et al., 2001; Advani et al., 2005;
Bates et al., 2001; Bauer et al., 2005; Chico et al., 2001). In addition,
many of these compounds inhibit cytochrome P450 enzymes, resulting
in unpredictable pharmacokinetic interactions.
Third-generation ABCB1 inhibitors (Table 3) were developed by
using quantitative structure-activity relationships (QSAR) and combi-
natorial chemistry, which specifically and potently inhibit the ABC
exporter at nanomolar concentrations, without affecting cytochrome
P450 enzymes (Coley, 2010; Dantzig et al., 2001; Palmeira et al.,
2012a; Silva et al., 2015). Often these compounds inhibit ABCB1 based
on a non-competitive mechanism; the most promising ones are possibly
tariquidar, elacridar and zosuquidar (Akhtar et al., 2011; Dantzig et al.,
2001; Fox and Bates, 2007; Hyafil et al., 1993; Weidner et al., 2016).
Zosuquidar, a difluoro-cyclopropyl dibenzosuberane derivative, is very
potent, is effective at nanomolar concentrations and has no interaction
with cytochrome P450 and with other drug efflux pumps (Bihorel et al.,
2007; Dantzig et al., 2001; Dantzig et al., 1999; Green et al., 2001;
Kemper et al., 2004). However, third-generation ABCB1 inhibitors have
encountered unexpected toxicity problems, and clinical trials have
yielded modest results (Pusztai et al., 2005; Ruff et al., 2009); for ex-
ample, a phase III trial for the treatment of AML and myelodysplastic
syndrome (MDS) using zosuquidar did not meet its primary endpoint
(Cripe et al., 2010).
Fourth-generation ABCB1 inhibitors (Table 3) include various
classes of compounds, i.e. natural compounds, surfactants and lipids,
peptides and molecules with dual activity (Palmeira et al., 2012a).
Hundreds of natural compounds, obtained from several natural sources,
and belonging to many chemical families, such as alkaloids, flavonoids,
coumarins, resins, saponins and terpenoids (Dewanjee et al., 2017),
have been described thus far as acting on ABC transporters, thereby
offering potential for semi-synthetic modification to produce new
scaffolds which could serve as valuable tools to evade the systemic
toxicities shown by synthetic counterparts. However, reports in the
literature are sometimes contradictory: for example quercetin has been
reported to have opposite effects on ABCB1 and MDR (Critchfield et al.,
1994; Phang et al., 1993; Rodgers and Grant, 1998) perhaps also due to
its inhibition of Cytochrome P-450 enzymes.
Surfactants have complex relationship with ABCB1-dependent drug
efflux and MDR; they alter membrane fluidity, perturbing lipid bilayers,
and drug-membrane partitioning; they also interact with ABCB1, inflict
modifications in secondary and tertiary enzyme structure, inhibit ABC
transporter activity and increase cellular drug accumulation (Regev
et al., 2007; Sharom, 2014; Shieh et al., 2011; Shukla et al., 2017).
Some peptides, such as reversins, are able to potently inhibit ABCB1
in a non-competitive manner (Arnaud et al., 2010); they have been
recently used as conjugate copolymers with anthracyclines to overcome
MDR (Koziolova et al., 2016; Sivak et al., 2017).
Dual ligands, able to simultaneously modulate ABCB1 and other
enzymes, have been recently described. Apart from their ability to
inhibit other ABC transporters shown by several inhibitors, dual ligands
include aminated thioxanthones, targeting ABCB1 and DNA-inter-
calating, and verapamil-like compounds, targeting ABCB1 and NO
synthase (Colabufo et al., 2011; Namanja-Magliano et al., 2017;
Palmeira et al., 2012b).
Other strategies to overcome ABCB1-dependent MDR
Collateral sensitivity (CS) is the ability of compounds to selectively
kill MDR cells over parental cells from which they were derived
(Pluchino et al., 2012). CS agents are MDR-selective compounds that
can act with different mechanisms; one of such mechanisms is apoptosis
via reactive oxygen species (ROS) overproduction following futile ATP
hydrolysis cycles in cells with high-ABCB1 levels, induced by iron-
chelating compounds such as Dp44mT or N-(2-hydroxy acetophenone)
glycinate (Ganguly et al., 2010; Jansson et al., 2010); Dp44mT also acts
by hijacking lysosomal ABCB1 (Jansson et al., 2015; Seebacher et al.,
2016). Other CS-inducing drugs exploit increased sensitivity to bioe-
nergy states: treatment with 2-deoxy-D-glucose, a hexokinase II in-
hibitor, induces apoptosis in MDR cells, that rely on glycolysis for ATP
generation due to the Warburg effect resulting from hypoxia in tumor
microenvironment (Bell et al., 1998; Kaplan et al., 1991).
Another strategy to overcome MDR in ABCB1-overexpressing cells is
the use of nanoparticle delivery of anticancer drugs. Nanoparticles that
are taken up by the cell via endocytosis often bypass and evade the ABC
transporters responsible for efflux of cytotoxic drugs once released into
the cytoplasm (Bar-Zeev et al., 2016; Bar-Zeev et al., 2017; Cerqueira
et al., 2015; Fracasso et al., 2016; Huang et al., 2011; Livney and
Assaraf, 2013; Shapira et al., 2011; Song et al., 2010; Yuan et al., 2016).
Drug inducers of ABCB1 expression
Cells exposed to a P-glycoprotein cytotoxic drug substrate either
upon stepwise selection or single dose exposure, frequently display the
MDR phenotype often due to high overexpression of ABCB1 levels,
frequently due to gene amplification or increased transcription (Assaraf
and Borgnia, 1994; Assaraf et al., 1989a, 1989b; Borgnia et al., 1996;
Fojo et al., 1985; Roninson, 1992; Roninson et al., 1986; Scotto et al.,
1986; Shen et al., 1986).
Many molecules (Table 4), and in particular many chemother-
apeutic drugs, induce ABCB1 overexpression via multiple mechanisms,
involving genomic amplification, upregulation of transcription, mRNA
splicing, transport and stability. Constitutive ABCB1 transcription
mostly depends on a few elements, i.e. two GC-rich regions (GC-boxes),
located from −110 to −103 and from −56 to −45 bases upstream of
the major +1 start site in the human ABCB1 promoter, the CCAAT box
(Y-box), the p53 element and possibly the AP-1 and T-cell factor ele-
ments (see above, for a review see (Silva et al., 2015)). In addition,
stress-induced upregulation of ABCB1 expression occurs, depending on
ROS, heat shock, inflammation and ionizing radiations, acting via a
wealth of transcription factors, such as phosphoinositide 3-kinase
(PI3K)/Akt, extracellular signal-regulated kinases (ERKs; or mitogen-
activated protein kinases, MAPKs), c-Jun NH2-terminal protein kinase
(JNK), protein kinase C (PKC) and nuclear factor-κB (NF-κB), cyclic
adenosine monophosphate responsive element (CRE) and heat-shock
factor (HSF), acting on several pathways in a very complex manner
(Callaghan et al., 2008; Chin et al., 1990; Krishnamurthy et al., 2012;
Labialle et al., 2002; Miyazaki et al., 1992; Nwaozuzu et al., 2003;
Scotto, 2003; Scotto and Egan, 1998; Silva et al., 2015; Vilaboa et al.,
2000; Wong et al., 2010; Zhou and Kuo, 1997).
ABCB1 can be induced by several stimuli, acting on these regulatory
elements, directly or indirectly. Apart from the stress conditions
abovementioned, many molecules are able to induce ABCB1 over-
expression. Table 4 reports a list of ABCB1 inducers, the mode they
have been described to act through, and the level of induction observed
upon cell treatment: these compounds are rather heterogeneous in
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Table 4
Drugs inducing ABCB1 expression.
Drugs inducing ABCB1 expression
Inducer Action
Abacavir 1.5-fold ABCB1 induction upon 15 μM treatment for 72 h in hCMEC/D3 cells (Chan et al., 2013)
N-Acetoxy-2-acetylaminofluorene 3.2-fold ABCB1 expression increase upon 40 μM treatment for 8 h in HepG2 cells (Kuo et al., 2002)
2-Acetyl-aminofluorene 7.5-fold ABCB1 induction upon 100 μM treatment for 24 h in rat hepatoma cells (Deng et al., 2001)
Actinomycin D 2.5-fold ABCB1 mRNA induction upon 400 ng/mL treatment for 72 h in human T lymphoblastoid CCRF-CEM cells (Gekeler et al., 1988)
Aflatoxin B1 ABCB1 mRNA induction upon 3 mg/kg i.p. treatment for 48 h in Fischer rats (Burt and Thorgeirsson, 1988)
Ambrisentan 2.3-fold ABCB1 expression upon 50 μM treatment for 96 h in LS180 cells (Weiss et al., 2013)
Amiodarone 2.4-fold ABCB1 induction upon 10 μM treatment for 72 h in LS180 cells (Schuetz et al., 1996)
Amprenavir 3.5-fold ABCB1 induction upon 10 μM treatment for 72 h in LS180 cells (Perloff et al., 2000)
Arsenite 3-fold ABCB1 induction upon 250 nM treatment for 24 h in TRL1215 cells (Liu et al., 2001)
Artemisinin 13.5-fold ABCB1 mRNA induction upon 10 μM treatment for 6 h in Caco-2 cells (Riganti et al., 2009b)
Asiatic acid 2.6-fold ABCB1 induction upon 25 μM treatment for 48 h in LS180 cells (Abuznait et al., 2011b)
Atazanavir 2.5-fold ABCB1 induction upon 10 μM treatment for 72 h in hCMEC/D3 cells (Zastre et al., 2009)
Atorvastatin 4-fold ABCB1 mRNA induction upon 10 μM treatment for 72 h in T84 cells (Haslam et al., 2008a)
Avermectin 2.6-fold ABCB1 induction upon 0.5 μM treatment for 12 h in Drosophila S2 cells (Luo et al., 2013)
Beclometasone 2.1-fold ABCB1 expression increase upon 50 μM treatment for 72 h in Caco-2 cells (Crowe and Tan, 2012)
Benzopyrene Increased ABCB1 expression upon 50 μM treatment for 72 h in Caco-2 cell (Sugihara et al., 2007)
Bethametasone 4-fold ABCB1 induction upon 0.4 μM treatment for 24 h in placenta cells (Manceau et al., 2012)
Bilirubin 18-fold ABCB1 mRNA induction upon 100 μM treatment for 24 h in T84 cells (Naruhashi et al., 2011)
Bosentan 3.7-fold ABCB1 induction upon 50 μM treatment for 96 h in LS180 cells (Weiss et al., 2013)
Bromocriptine 10-fold ABCB1 induction upon 100 μM treatment for 24 h in rat Reuber H35 cells (Furuya et al., 1997)
Budesonide 1.6-fold ABCB1 induction upon 50 μM treatment for 72 h in Caco-2 cells (Maier et al., 2007)
Cadmium 3.7-fold ABCB1 induction upon 10 μM treatment for 72 h in Caco-2 cells (Thevenod et al., 2000)
Caffeine Increased ABCB1 expression upon 5–100 μM treatment for 48 h in LS180 cells (Abuznait et al., 2011a)
Capsaicin 2-fold ABCB1 induction upon 50 μM treatment for 72 h in Caco-2 cells (Han et al., 2006)
Carbamazepine 7.6-fold ABCB1 induction upon 50 μM treatment for 72 h in human blood lymphocytes (Owen et al., 2006)
Catechine 2.3-fold ABCB1 induction upon 10 μM treatment for 4 weeks in Caco-2 cells (Lohner et al., 2007)
Celiprolol 3.2-fold ABCB1 induction upon 100 μM treatment for 72 h in Caco-2 cells (Anderle et al., 1998)
Cembratriene 3-fold ABCB1 induction upon 25 μM treatment for 48 h in LS180 cells (Abuznait et al., 2011b)
Cholate 1.8-fold ABCB1 mRNA induction upon 100 μM treatment for 24 h in T84 cells (Naruhashi et al., 2011)
Chrysin 2.8-fold ABCB1 induction upon 10 μM treatment for 4 weeks in Caco-2 cells (Lohner et al., 2007)
Ciclesonide 1.7-fold ABCB1 induction upon 50 μM treatment for 72 h in Caco-2 cells (Crowe and Tan, 2012)
Cisplatin 2.7-fold ABCB1 expression upon 3 mg/kg treatment for 96 h in liver and kidney of Sprague-Dawley rats (Demeule et al., 1999)
Clotrimazole 4.1-fold ABCB1 induction upon 10 μM treatment for 72 h in LS180 cells (Schuetz et al., 1996)
Colchicine 1.8-fold ABCB1 induction upon 100 μM treatment for 24 h in Caco-2 cells (Silva et al., 2014)
Colupulones 1.3-fold ABCB1 induction upon 1 μM treatment for 48 h in LS180 cells (Bharate et al., 2015)
Cyanidin 2.7-fold ABCB1 induction upon 10 μM treatment for 4 weeks in Caco-2 cells (Lohner et al., 2007)
Cycloheximide 27-fold ABCB1 mRNA induction upon 10 μM treatment for 24 h in RC3 cells (Gant et al., 1992)
Cyclosporine A 2-fold ABCB1 mRNA induction upon 5 μg/mL treatment for 48 h in LS180 cells (Herzog et al., 1993)
Cytarabine 1.3-fold ABCB1 induction upon 0.5 μM treatment for 24 h in HL60 leukemia cells (Prenkert et al., 2009)
Dadzein 1.7-fold ABCB1 induction upon 10 μM treatment for 4 weeks in Caco-2 cells (Lohner et al., 2007)
Daunorubicin 3-fold ABCB1 induction upon 1.5 μg/mL treatment for 4 h in CEM/A7R cells (Hu et al., 1995)
Daurunavir 1.7-fold ABCB1 induction upon 10 μM treatment for 72 h in hCMEC/D3 cells (Chan et al., 2013)
Depsipeptide 6.3-fold ABCB1 mRNA induction upon 5 ng/mL treatment for 72 h in 108 renal carcinoma cells (Robey et al., 2006)
Dexamethasone 2.9- and 1.9-fold ABCB1 expression upon 50 mg/kg7day treatment for 96 h in intestine and liver, respectively, of Wistar rats (Kageyama
et al., 2006)
Digoxin 92-fold ABCB1 mRNA induction upon 1 μM treatment for 72 h in T84 cells (Haslam et al., 2008b)
1,25-Dihydroxyvitamin D3 5.9-fold ABCB1 induction upon 2.5 μg/kg/day treatment for 8 days in fxr(-/-) mice kidney (Chow et al., 2011)
Diltiazem 4-fold ABCB1 mRNA induction upon 10 μg/mL treatment for 48 h in LS180 cells (Herzog et al., 1993)
Docetaxel Increased ABCB1 expression upon 10 μM treatment for 48 h in LS180 cells (Harmsen et al., 2010)
Doxorubicin Increased ABCB1 and ABCB1 mRNA expression upon 3 μM treatments in MCF-7 cells (Mealey et al., 2002)
Doxycycline 8-fold increased ABCB1 expression upon 100 μg/mL treatment for 12 weeks in MCF-7 cells (Mealey et al., 2002)
Efavirenz 8-fold increased ABCB1 expression upon 10 μM treatment for 72 h in hCMEC/D3 cells (Chan et al., 2013)
Epigallocatechin-3-gallate 2.2-fold ABCB1 induction upon 10 μM treatment for 4 weeks in Caco-2 cells (Lohner et al., 2007)
Epirubicin 3-fold ABCB1 induction upon 1.5 μg/mL treatment for 8 h in CEM/A7R cells (Hu et al., 1995)
Eriodictyol 2.1-fold ABCB1 induction upon 10 μM treatment for 4 weeks in Caco-2 cells (Lohner et al., 2007)
Erlotinib 2.9-fold ABCB1 induction upon 10 μM treatment for 48 h in LS180V cells (Harmsen et al., 2013)
Erythromycin 3.3-fold ABCB1 induction upon 15 mg/kg treatment for 7 days in Rhesus monkey livers (Gant et al., 1995)
β-Estradiol 4-fold ABCB1 mRNA induction upon 50 μM treatment for 48 h in LS180 cells (Abuznait et al., 2011a)
Ethinylestradiol 1.6-fold ABCB1 induction upon 0.5 pM treatment for 48 h in Caco-2 cells (Arias et al., 2014)
Fascaplysin 7-fold ABCB1 induction upon 1 μM treatment for 48 h in LS180 cells (Manda et al., 2016)
Flavone 3-fold ABCB1 induction upon 10 μM treatment for 4 weeks in Caco-2 cells (Lohner et al., 2007)
5-Fluorouracil 4.5-fold ABCB1 induction upon 2 μg/mL treatment for 72 h in CEM/A7R cells (Hu et al., 1999)
Fluticasone +87% ABCB1 induction upon 50μM treatment for 72 h in Caco-2 cells (Crowe and Tan, 2012)
Gefinitib 3-fold ABCB1 induction upon 10 μM treatment for 48 h in LS180V cells (Harmsen et al., 2013)
Genistein 2-fold ABCB1 induction upon 10 μM treatment for 4 weeks in Caco-2 cells (Lohner et al., 2007)
Hyperforin 3-fold ABCB1 induction upon 150 nM treatment for 48 h in LS180 cells (Abuznait et al., 2011a)
Hypericin 7-fold ABCB1 induction upon 3 μM treatment for 72 h in LS180V cells (Perloff et al., 2001)
Idarubicin 4-fold ABCB1 induction upon 0.1 μg/mL treatment for 24 h in CEM/A7R cells (Hu et al., 1999)
Indinavir 1.6-fold ABCB1 induction upon 10 μM treatment for 72 h in LS180V cells (Perloff et al., 2000)
Insulin +89% ABCB1 induction upon 10 U/kg/day treatment for 5 weeks in Sprague-Dawley rats (Liu et al., 2008)
Ivermectin 2-fold ABCB1 induction upon 10 μM treatment for 72 h in JWZ murine hepatic cells (Menez et al., 2012)
Lopinavir 2.3-fold ABCB1 induction upon 10 μM treatment for 72 h in hCMEC/D3 cells (Chan et al., 2013)
(continued on next page)
I. Genovese et al. Drug Resistance Updates 32 (2017) 23–46
32
nature, structure and origin. ABCB1 inducers include many drugs
(among which several chemotherapeutic drugs and tyrosine kinase in-
hibitors, usually also ABCB1 substrates), natural compounds and
marine compounds, and phosphodiesterase-5 inhibitors.
The ABCB1 amplicon
MDR and the genes in the human ABCB1 amplicon
The human ABCB1 (MDR1) gene resides in chromosome 7q21.1
region (Callen et al., 1987); its ability to confer MDR when over-
expressed or amplified (Callen et al., 1987; Fojo et al., 1987;
Schoenlein, 1993; Scotto et al., 1986; Van der Bliek et al., 1986b) and
the increase in ABCB1 expression upon chemotherapeutic drug treat-
ment (Abolhoda et al., 1999; Atalay et al., 2006; Brugger et al., 2002;
Chin et al., 1990; Gekeler et al., 1988; Hu et al., 1995; Liu et al., 2002;
Park et al., 1994; Schneider et al., 1993) have been largely reported
throughout the years.
The amplification of chromosome 7q21 region in neuroblastoma
cancer cell lines (Flahaut et al., 2006), as well as the increased copy
number of 7q21.12 region (including ABCB1 gene) in lung cancer cells
(Kitada and Yamasaki, 2007) and in leukemia cells (Kadioglu and
Efferth, 2016) correspond to drug resistance, suggesting the possible
participation of other genes in the development of the MDR phenotype.
Genomic instability and chromosomal rearrangements often affect
cancer cells, resulting in genomic amplification, frequently translated in
an increased copy number of the ABCB1 gene that leads to a marked
transactivation of ABCB1 gene overexpression (Chen et al., 2002;
Duesberg et al., 2007; Katoh et al., 2005; Kim et al., 2015; Mickley
et al., 1997; Pang et al., 2005). These genomic rearrangements may
either occur in upstream regions far from the ABCB1 promoter or may
affect genomic alterations along the 7q chromosomal arm that can
correlate with ABCB1 activation (Chen et al., 2002; Knutsen et al.,
1998).
Genomic investigations focusing on the ABCB1 amplicon have been
undertaken in order to understand whether or not the surrounding
genes might have some role in the development of the MDR phenotype
or if they were co-amplified or suppressed in resistance-induced cancer
cell lines. ABCB1 gene expression can be increased up to 1000-fold in
lung cancer cells with acquired paclitaxel resistance, showing a sur-
prising discrepancy between the gene copy number and the expression
level. Along with ABCB1 gene expression enhancement, within the
same amplicon (7q21.12), there is a concomitant co-amplification of
RPIB9 (RUNDC3B) and ADAM22 with an increased fold change of 38.5
and 27.7, respectively (Yabuki et al., 2007).
Taxane-induced MDR ovarian cancer cell lines showed a regional
activation on chromosome 7q21.11-13 of about 22 co-expressed genes
over an area of 8Mb, surrounding the ABCB1 gene. These genes include
SRI (Sorcin), MGC4175 (TMEM243), DMTF1, CROT, ABCB1, ABCB4,
ADAM22, RUNDC3B, DBF4 and the regional activation was driven by
Table 4 (continued)
Drugs inducing ABCB1 expression
Inducer Action
Mangiferin 2.4-fold ABCB1 induction upon 200 μM treatment for 72 h in HK2 cells (Chieli et al., 2010)
Methylprednisolone +50% ABCB1 induction upon 50 μM treatment for 72 h in Caco-2 cells (Crowe and Tan, 2012)
Midazolam 5.9-fold ABCB1 induction upon 10 μM treatment for 72 h in LS180 cells (Schuetz et al., 1996)
Mitoxantrone 30/100-fold ABCB1 mRNA induction upon 1 μg/mL treatment for 8 h in NIH 3T3 cells (Schrenk et al., 1996)
Morphine 2-fold ABCB1 induction upon 20 mg/kg/day treatment for 5 days in Sprague-Dawley rat brains (Aquilante et al., 2000)
Myricetin 2.5-fold ABCB1 induction upon 10 μM treatment for 4 weeks in Caco-2 cells (Lohner et al., 2007)
Naringenin 1.8-fold ABCB1 induction upon 10μM treatment for 4 weeks in Caco-2 cells (Lohner et al., 2007)
Nelfinavir 3.5-fold ABCB1 induction upon 10 μM treatment for 72 h in LS180V cells (Perloff et al., 2000)
Nevirapine 1.6-fold ABCB1 induction upon 15 μM treatment for 72 h in hCMEC/D3 cells (Chan et al., 2013)
Nicardipine 6-fold ABCB1 mRNA induction upon 10 μM treatment for 48 h in LS180 cells (Herzog et al., 1993)
Nifedipine 4-fold ABCB1 mRNA induction upon 5 μg/mL treatment for 48 h in LS180 cells (Herzog et al., 1993)
Nilotinib 3.6-fold ABCB1 induction upon 10 μM treatment for 48 h in LS180V cells (Harmsen et al., 2013)
Oleocanthal 2.3-fold ABCB1 induction upon 25 μM treatment for 48 h in LS180 cells (Abuznait et al., 2011b)
Ouabain 3.4-fold ABCB1 mRNA induction upon 1 μM treatment for 24 h in HT29 cells (Riganti et al., 2009a)
Oxycodone 4-fold ABCB1 induction upon 5 mg/kg/day treatment for 8 days in Sprague-Dawley rat livers (Hassan et al., 2007)
Paclitaxel Increased ABCB1 expression upon 10 μM treatment for 48 h in LS180 cells (Harmsen et al., 2010)
Parthenolide 6-fold ABCB1 mRNA induction upon 10 μM treatment for 6 h in HT29 cells (Riganti et al., 2009b)
Phenobarbital 14-fold ABCB1 induction upon 1 mM treatment for 72 h in LS180 cells (Schuetz et al., 1996)
Phenothiazine 6.5-fold ABCB1 expression upon 50 mg/kg/day treatment for 72 h in bile canalicular membrane vesicles of Wistar rats (Watanabe et al.,
1995)
Phenytoin ABCB1 induction upon 50 mg/kg/day treatment for 21 days in Sprague-Dawley rat brains (Wen et al., 2008)
Piperine 2-fold ABCB1 expression upon 100 μM treatment for 72 h in Caco-2 cells (Han et al., 2008)
Pregnenolone-16α- carbonitrile +53% ABCB1 expression upon 5 μM treatment for 6 h in brain capillaries from CB6F1 rats (Bauer et al., 2006)
Propranolol 4-fold ABCB1 induction upon 200 μM treatment for 24 h in LS180 cells (Collett et al., 2004)
Quercetin 2.5-fold ABCB1 induction upon 10 μM treatment for 4 weeks in Caco-2 cells (Lohner et al., 2007)
Rapamycin 4.9-fold ABCB1 induction upon 10 μM treatment for 72 h in LS180 cells (Schuetz et al., 1996)
Reserpine 29-fold ABCB1 induction upon 10μM treatment for 72 h in LS180 cells (Schuetz et al., 1996)
Retinoic acid 20-fold ABCB1 mRNA induction upon 5 μM treatment for 72 h in SK-N-SH cells (Bates et al., 1989)
Rifampicin 16-fold ABCB1 induction upon 10 μM treatment for 72 h in LS180 cells (Schuetz et al., 1996)
Ritonavir 4.2-fold ABCB1 induction upon 10 μM treatment for 72 h in LS180V cells (Perloff et al., 2000)
Saquinavir 2.4-fold ABCB1 induction upon 10 μM treatment for 72 h in LS180V cells (Perloff et al., 2000)
Sildenafil 2.1-fold ABCB1 induction upon 5 μM treatment for 96 h in LS180 cells (Weiss et al., 2013)
Tacrolimus 3.2-fold ABCB1 induction upon 10 μM treatment for 72 h in LS180 cells (Schuetz et al., 1996)
Tadalafil 3.3-fold ABCB1 induction upon 20 μM treatment for 96 h in LS180 cells (Weiss et al., 2013)
Tamoxifen 6-fold ABCB1 induction upon 50 mg/kg/day treatment for 7 days in Rhesus monkey livers (Gant et al., 1995)
Taxifolin 1.8-fold ABCB1 induction upon 10 μM treatment for 4 weeks in Caco-2 cells (Lohner et al., 2007)
γ-Tocotrienol 2.4-fold ABCB1 induction upon 25 μM treatment for 48 h in LS180 cells (Abuznait et al., 2011b)
Trichostatin A 20-fold ABCB1 mRNA induction upon 100 ng/mL treatment for 24 h in SW620 cells (Jin and Scotto, 1998)
Verapamil 3-fold ABCB1 induction upon 10 μM treatment for 72 h in Caco-2 cells (Anderle et al., 1998)
Vinblastine 7.5-fold ABCB1 induction upon 0.011 μM treatment for 72h in Caco-2 cells (Anderle et al., 1998)
Vincristine ABCB1 induction upon 0.1 μM treatment for 48 h in LS180 cells (Harmsen et al., 2010)
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gene copy number gains (Wang et al., 2006). Another study on taxane-
resistant breast cancer cell lines reported gains in gene copy number on
chromosome 7, specifically concerning ABC transporters (ABCB1,
ABCB4), SRI, DMTF1, SLC25A40 and CROT, all belonging to the ABCB1
amplicon (Hansen et al., 2016). Furthermore, a whole-genome char-
acterization study on chemoresistant ovarian cancer cells reported an
intergenic deletion between ABCB1 and SLC25A40 genes and that re-
sults in the creation of a fused transcript, with no evidence of this event
in drug-sensitive tumor samples. Additional transcriptome investiga-
tions showed the increase of ABCB1-SLC25A40 fused transcript in
chemoresistant human ovarian cancer samples and the decrease of
SLC25A40 in drug sensitive specimens (Patch et al., 2015).
However, the genomic rearrangements and the high copy number
cannot explain by themselves the unexpected high level increase in
gene expression, suggesting that other mechanisms as such transcrip-
tional upregulation, mRNA stabilization, post-transcriptional regulation
and epigenetic modifications may contribute to this enhanced gene
expression. Interestingly, non-coding RNAs as miRNAs and long non-
coding RNAs (lncRNA) may exert post-transcriptional regulatory func-
tions in cancer cells, giving rise to metastatic or drug-resistant pheno-
types. Indeed in the ABCB1 amplicon a lncRNA (TP53TG1) resides,
reported to be down-regulated in A549 cisplatin-resistant lung cancer
cells (Yang et al., 2013). On the other hand, deletions in the ABCB1
genes locus in breast cancer patients determine a 2–8-fold decreased
expression of these MDR locus-related genes; cancer patients harboring
these deletions display a better response to neoadjuvant chemotherapy
(Litviakov et al., 2016).
Overall, many published studies report that a genomic amplification
of chromosome 7q21.12 region, where ABCB1 and related genes reside
(Fig. 5), occurs in MDR tumors, and that amplification and or over-
expression of these genes contributes to the MDR phenotype (Bonte
et al., 2008; Chao et al., 1991; Cheng et al., 2013; Finalet Ferreiro et al.,
2014; Flahaut et al., 2006; Hansen et al., 2016; Januchowski et al.,
2017; Kadioglu and Efferth, 2016; Kitada and Yamasaki, 2007; Lee
et al., 2017; Litviakov et al., 2016; Patch et al., 2015; Sasi et al., 2017;
Torigoe et al., 1995; Van der Bliek et al., 1988; Van der Bliek et al.,
1986a; Van der Bliek et al., 1986b; Yabuki et al., 2007). The core of the
amplicon is formed by the genes Sorcin (SRI), ADAM22, DBF4,
SLC25A40, RUNDC3B (RPIP9), ABCB1, ABCB4, CROT, TP53TG1
lncRNA, TMEM243 (MGC4175) and DMTF1 (DMP1) (Fig. 5). All of
these genes have been found to be associated with tumorigenesis and
MDR; very important contributions to the MDR phenotype are due in
particular to the overexpression of DBF4 and Sorcin, which are con-
sidered as important markers of poor prognosis and drivers of MDR in
several types of cancers, acting on different mechanisms with respect to
ABCB1. Selective inhibitors of Sorcin expression and of CDC7-DBF4
activity have been recently developed, and are considered good po-
tential anti-tumor candidates (see below).
ABCB1 amplicon genes: regulation, cancer and MDR
Sorcin (SRI)
Sorcin was originally isolated by Meyers and Biedler in 1981 as a
soluble, low molecular weight protein in hamster lung cancer cell line
resistant to vincristine, and this feature was used to give sorcin the
name of Sorcin (SOluble Resistance-related Calcium binding protein)
(Meyers and Biedler, 1981). Sorcin belongs to the penta EF-hand (PEF)
protein family; as other members of this family, upon calcium binding,
Sorcin undergoes a conformational change, leading to the exposure of
hydrophobic surfaces that enable the interaction with membranes and
other binding partners (Ilari et al., 2015). Among them, Sorcin binds
and controls proteins involved in the regulation of intracellular calcium
concentration as Ryanodine Receptors (RyRs), Sarco/endoplasmic re-
ticulum Ca2+-ATPase (SERCA pumps) and Na+/Ca2+exchanger (NCX),
leading to the termination of contraction and the onset of relaxation
(Colotti et al., 2014; Franceschini et al., 2008; Zamparelli et al., 2010).
Sorcin is phosphorylated by several kinases involved in cell cycle pro-
gression or calcium homeostasis, regulating calcium load in storage
organelles and vesicle trafficking (Lalioti et al., 2014).
Sorcin is overexpressed in many cancers of distinct tissue origin,
especially those displaying the ABCB1-dependent MDR phenotype. The
Sorcin gene resides in the same amplicon of ABCB1 and was identified
as a resistance–related gene because its genomic locus is co-amplified
along with ABCB1 in cancer cells displaying the MDR phenotype (Van
der Bliek et al., 1986a). Although for many years Sorcin overexpression
was thought to be an accidental by-product of this genomic co-ampli-
fication process (Van der Bliek et al., 1988), a large body of published
studies considered Sorcin both as a marker and a cause of MDR. Sorcin
is found overexpressed in many human tumors including lymphoma,
leukemia, gastric cancer, lung cancer, adenocarcinoma, breast cancer,
nasopharyngeal cancer and ovarian cancer, particularly in malignancies
with the ABCB1-dependent MDR phenotype (Deng et al., 2010; Gao
et al., 2015; Padar et al., 2004; Qi et al., 2006; Qu et al., 2010; Sun
et al., 2017; Tan et al., 2003; Yamagishi et al., 2014; Yang et al., 2008;
Zhou et al., 2006).
Many studies have dissected the role of Sorcin in MDR cancer types,
indicating its role as an oncoprotein. In doxorubicin-resistant K562/
A02 leukemia cell lines, Sorcin was found consistently up-regulated
compared to the drug-sensitive parental cell line, and the over-
expression in the resistant line conferred MDR (Hu et al., 2013; Qi et al.,
2006; Sun et al., 2017; Yamagishi et al., 2014; Zhou et al., 2006). Sorcin
expression levels in leukemia patients generally correlate with low-re-
sponse to chemotherapies and poor prognosis. Moreover, Sorcin over-
expression by gene transfection resulted in increased drug resistance to
a variety of chemotherapeutic agents, including doxorubicin, etoposide,
homoharringtonine and vincristine in K562 cells; and conferred drug
resistance to vincristine, adriamycin, paclitaxel and 5-fluorouracil in
SGC7901 cells, ovarian and breast cancer, thereby confirming the
ability of Sorcin overexpression to enhance drug resistance. Con-
sistently, inhibition of Sorcin expression by RNA interference techni-
ques led to reversal of MDR in many tumor cell lines, as MDR K562/
A02 and Sorcin-transfected K562, MCF-7/A02, HeLa, colorectal cancer
and CNE2/DDPls (Colotti et al., 2014; Dabaghi et al., 2016; Gao et al.,
2015; Gong et al., 2014; Hamada et al., 1988; He et al., 2011; Hu et al.,
2013; Hu et al., 2014; Kawakami et al., 2007; Liu et al., 2014;
Maddalena et al., 2011; Parekh et al., 2002; Sun et al., 2017; Zhou
et al., 2006).
Additionally, a recent study showed that directed siRNA-Sorcin si-
lencing decreased ABCB1 protein levels in a H1299 lung cancer cell
line, with a consequent increase in rhodamine123 efflux out of the cells,
confirming a direct relationship between Sorcin and regulation of
ABCB1 transport activity in MDR cells. Besides, Sorcin is able to bind
Fig. 5. The ABCB1 amplicon. Genes in the 7q21.12 region are shown.
I. Genovese et al. Drug Resistance Updates 32 (2017) 23–46
34
directly doxorubicin, paclitaxel, vinblastine and cisplatin, acting as a
protein drug sink thus hampering nuclear uptake of doxorubicin, thus
allowing cell survival (Genovese et al., 2017). Sorcin is highly ex-
pressed and is able to bind doxorubicin with high affinity on the EF5-
hand (Fig. 6), which does not bind calcium and is involved in homo-
dimer formation (Genovese et al., 2017).
Furthermore, Sorcin silencing inhibits the epithelial-to-mesench-
ymal (EMT) transition in the human breast cancer MDA-MB-213 cell
line, possibly via E-cadherin and VEGF expression, and reduces breast
cancer metastasis, while Sorcin overexpression increases migration and
invasion in vitro (Hu et al., 2014). Sorcin expression levels are sig-
nificantly up-regulated in hepatocellular carcinoma (HCC) tumors
compared with matched adjacent non-tumor liver tissues and normal
liver tissues, and expression levels correlate with HCC metastasis. HCC
patients with high Sorcin expression had both shorter survival and
higher recurrence than those with low Sorcin expression. Sorcin ex-
pression is therefore an independent and significant risk factor for
survival and recurrence of HCC patients. Sorcin can promote HCC and
colorectal cancer cell proliferation, migration, and invasion in vitro, and
facilitate cancer growth, metastasis and EMT, by activating extra-
cellular signal-regulated kinase (ERK) and/or PI3K/Akt signaling
pathways (Lei et al., 2017; Tong et al., 2015).
Several groups are currently studying the role of Sorcin in the de-
velopment of MDR in cancer cells, disclosing intriguing findings.
Yamagishi and collaborators found that Sorcin expression correlates
with ABCB1 up-regulation, indeed Sorcin induced ABCB1 expression
through a cAMP response element (CRE) located within −716 and
−709 bp in the ABCB1 gene. Consistently, they found that up-regula-
tion of Sorcin induces ABCB1 expression through the inducible acti-
vation of CREB (cAMP response element-binding protein) pathway in-
creasing the phosphorylation of CREB1 and its binding to the CRE
binding site in the ABCB1 promoter (Yamagishi et al., 2014).
A shorter isoform (18 KDa) of Sorcin, identified to be located in
mitochondria, is the aim of the quality control system operated by ER-
associated TRAP1. The latter protein is up-regulated in several human
tumors and can modulate apoptosis; indeed, transfection experiments of
a TRAP1 deletion mutant in TRAP1-silenced cells increased the ex-
pression of mitochondrial sorcin and protected cells from apoptosis
upon treatment with ER stress agents and paclitaxel (Maddalena et al.,
2013), suggesting a putative post-transcriptional regulation of sorcin
expression. Sorcin, loading calcium in ER and mitochondria, partici-
pates in the prevention of ER stress and unfolded protein response, and
increases cell escape from apoptosis (Lalioti et al., 2014; Maddalena
et al., 2011; Maddalena et al., 2013), shifting the equilibrium between
cell life and death towards proliferation in MDR cancer cells over-
expressing Sorcin.
For these reasons, Sorcin is an interesting oncoprotein and MDR
marker, able to bind several chemotherapeutic drugs, whose over-
expression results in the MDR phenotype. Sorcin expression is directly
linked to ABCB1 up-regulation, and is itself involved in regulation of
the ABCB1-dependent MDR phenotype. The modulation of Sorcin ex-
pression and activity (Li et al., 2016a; Sun et al., 2017) is emerging as a
possible strategy for overcoming tumorigenesis, cancer-related EMT
and MDR.
ADAM22
ADAM22 is a non-catalytic metalloprotease involved in both reg-
ulation of cell adhesion and spreading and inhibition of cell prolifera-
tion. It acts as a neuronal receptor for LGI1 and as a ligand with the
integrin αvβ3 and also with integrin dimers containing α6 or α9 in the
brain (D’Abaco et al., 2006), thus regulating synaptic transmission
(Fukata et al., 2006; Liu et al., 2009). In ovarian cell lines and in two
different human breast cancer cell lines, MCF-7 and MDA-MB-231,
exposure to docetaxel induced resistance to the drug, accompanied by
overexpression of ADAM22 and many other proteins of the ABCB1
amplicon (Hansen et al., 2016; Wang et al., 2006). Microarray analysis
uncovered that ADAM22 is overexpressed in doxorubicin-resistant os-
teosarcoma cell lines (Ma et al., 2017). ADAM22 is a target of SRC1,
steroid co-activator protein 1; in this respect, SRC1 overexpression
enhances ADAM22 expression in endocrine-sensitive MCF-7 breast
cancer cells. An enrichment of SRC1 was found at the ADAM22 pro-
moter through chromatin immunoprecipitation (ChIP) experiments in
endocrine-resistant breast cancer but not in the sensitive one, sug-
gesting the ability of this protein to promote tumor progression. SRC1-
dependent ADAM22 expression in response to tamoxifen has been ob-
served; ADAM22 is considered a prognostic and therapeutic drug target
in the treatment of endocrine-resistant breast cancer. Further, ADAM22
gene methylation is associated with malignant transformation of
ovarian endometriosis (Bolger and Young, 2013; McCartan et al., 2012;
Ren et al., 2014).
DBF4
DBF4 is a positive regulatory subunit of the CDC7 kinase that plays a
central role in DNA replication and cell proliferation, being essential for
the progression through the S phase. Indeed, the DBF4-CDC7 complex
phosphorylates the Mcm2 helicase at Ser40 and Ser53, thereby al-
lowing the initiation of eukaryotic DNA replication. CDC7 levels appear
to be constant throughout the cell cycle, whereas DBF4 levels have a
burst in late G1 phase and decrease at the end of mitosis (Cheng et al.,
2013; Pasero et al., 1999; Weinreich and Stillman, 1999). CDC7-DBF4 is
essential for the initiation of DNA replication; during the G1 phase
CDC7-DBF4 is down-regulated by RAD53-dependent phosphorylation
of DBF4, which allows origin licensing and prevents premature re-
plication initiation (Zegerman and Diffley, 2010), while in the S phase,
the intra-S-phase checkpoint is activated by CDC7-DBF4, by removing
the inhibitory activity of Mcm4 (Sheu and Stillman, 2010).
DBF4 has three motifs, N, M and C, which regulate its interaction
with various binding partners. The N motif is located at the N-terminus
of the protein and is believed to interact with ORC and RAD53, a kinase
required for check-point mediated cell cycle arrest (Duncker et al.,
2002). The C and N motifs are involved in the response towards gen-
otoxic agents, while less is known about the M motif (Fung et al., 2002),
even though it seems to have a role in cell proliferation, since it med-
iates the interaction with Mcm2 (Varrin et al., 2005).
Fig. 6. Structure of Sorcin in complex with doxorubicin. The two monomers of Sorcin are
indicated in cyan and orange, and doxorubicin in magenta sticks. The residues involved in
doxorubicin binding are indicated and represented as sticks; calcium ions are represented
as green spheres (Genovese et al., 2017). (For interpretation of the references to colour in
this figure legend, the reader is referred to the web version of this article.)
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Both CDC7 and DBF4 are overexpressed in many cancer cell lines
and primary tumors; tumor cell lines with increased CDC7 protein le-
vels also have increased DBF4, whose gene can be present in extra
copies in some tumors (Bonte et al., 2008; Cheng et al., 2013). Over-
expression of CDC7-DBF4 has been reported in many human tumors,
including ovarian cancer, colorectal cancer, melanoma, diffuse large B-
cell lymphoma, oral squamous cell carcinoma and breast cancer, and is
correlated with poor prognosis and advanced grade tumor grade (Bonte
et al., 2008; Chen et al., 2013a; Cheng et al., 2013; Choschzick et al.,
2010; Clarke et al., 2009; Hou et al., 2012; Kulkarni et al., 2009;
Nambiar et al., 2007). A high correlation between loss of p53 function
and up-regulation of DBF4 and CDC7 is observed in primary breast
cancer, suggesting that the increased amount of CDC7-DBF4 is pre-
sumably a common driver mutation for this malignancy (Bonte et al.,
2008). Higher DBF4-expressing melanomas were associated with lower
relapse-free survival, and higher proliferation (Nambiar et al., 2007).
High expression of CDC7-DBF4 correlates with poor prognosis in pa-
tients with large B-cell lymphoma (Hou et al., 2012), and is a marker of
resistance to DNA-damaging compounds in oral carcinoma (Cheng
et al., 2013), and a marker of chemoresistance to cisplatin, mitomycin
C, taxol, hydroxyurea and etoposide in lung adenocarcinoma and
bladder cancer (Sasi et al., 2017). 6-fold overexpression of DBF4 was
recently found in docetaxel-resistant prostate cancer cells with respect
to docetaxel-sensitive cells (Lee et al., 2017), and overexpression of
DBF4 was acquired during progression towards docetaxel resistance in
taxane-treated breast cancer cells (Hansen et al., 2016).
MiR29a regulates BPDE-induced DNA damage response (and de-
termines increased cell lethality) through repression of CDC7-DBF4
kinase expression in lung cancer cells, while overexpression of CDC7-
DBF4 determines resistance to BPDE (Barkley and Santocanale, 2013).
Further, CDC7-DBF4 is highly expressed in colorectal cancer and is
considered a potential therapeutic target in cancers with high p53 ex-
pression and an independent prognostic biomarker in colorectal cancer
enabling to select patients for adjuvant anti-CDC7-DBF4 treatment
(Melling et al., 2015). Since the CDC7-DBF4 kinase is considered a
novel and promising cancer target, inhibitors of the CDC7-DBF4 kinase
have been recently developed, and are considered good potential anti-
tumor candidates: in particular, the benzofuropyrimidinone XL413 is a
selective inhibitor, able to arrest cell cycle and inhibit tumor growth in
a Colo-2015 xenograft model (Koltun et al., 2012); pyridinyl-pyrrole
derivative compounds (such as PHA-767491) have antitumor activity
on glioblastoma, pancreatic cancer, breast cancer and other tumors
(Erbayraktar et al., 2016; Montagnoli et al., 2008; Natoni et al., 2011;
Sasi et al., 2017).
SLC25A40
SLC25A40 belongs to the solute carrier 25 (SLC25) nuclear-encoded
protein family residing on mitochondrial membranes, and in some cases
in other organelle membranes, and protects mitochondria from oxida-
tive stress (Palmieri, 2013). These proteins are widely expressed in
eukaryotic cells and they possess conserved structural features as, a
tripartite structure, six hydrophobic transmembrane α-helices and a 3-
fold repeated signature motif. Members of this family can vary by the
nature and size of the transported substrates, for the modes of transport
and driving force (Palmieri, 2013).
SLC25A40 mRNA and SLC25A40 protein are highly expressed in
brain and central nervous system (Haitina et al., 2006). Valach and
coworkers reported a relationship between SLC25A40 overexpression
and tumorigenesis, and they found it to be also activated in cancer-
associated fibroblasts (Valach et al., 2012).
SLC25A40 was reported to be overexpressed in drug-resistant
cancer cell (Hansen et al., 2016), and an ABCB1-SLC25A40 fused
transcript product was observed in resistant ovarian cancer cells (Patch
et al., 2015); its precise role in MDR has not been fully elucidated yet.
RUNDC3B (RPIP9)
RUNDC3B (RUN domain-containing protein 3B) function has not
been determined yet, but it is known to contain a RUN domain used to
interact with RAP2 (explaining the alternative name RAP2 binding-
protein 9, RPIP9), a RAS-protein involved in the MAPK cascade.
RUNDC3B also contains a binding site for MAPK signaling pathway
intermediates, being in the middle between RAP2 and MAPK pathway,
thus it is likely to be involved in the RAS-like GTPase signaling pathway
(Burmeister et al., 2017; Finalet Ferreiro et al., 2014).
Both RUNDC3B isoforms are highly expressed in brain tissue;
RUNDC3B is activated in tumorigenic breast cancer cell lines and in the
breast cancer primary tumor (Raguz et al., 2005).
RUNDC3B is in the same amplicon of ABCB1 and is transcribed from
the complementary DNA strand of the ABCB1 gene (Fig. 5); it may
interfere with alternative regulation of ABCB1 promoter regulation.
Treatment with histone deacetylases inhibitors (iHDACs) of colon and
pancreatic carcinomas results in an increased expression of ABCB1 and
RUNDC3B mRNAs (Balaguer et al., 2012). In addition, both ABCB1 and
RUNDC3B overexpression was found in breast cancer cells compared to
normal tissues, with a correlation between this overexpression and poor
prognosis in breast cancer (Raguz et al., 2005).
Integrative genomic studies report an increased expression of
RUNDC3B in paclitaxel-resistant ovarian cancer cells (Januchowski
et al., 2017) and a correlation between tumor growth advantage and
chemoresistance in hepatosplenic T-cell lymphoma where a gain of
chromosome 7q arm corresponds to an up-regulation of RUNDC3B
(Finalet Ferreiro et al., 2014).
ABCB4 (PGY3, MDR3)
ABCB4, a member of ABC transporters, is encoded by the ABCB4
(MDR3) gene, and is an ATP-dependent phospholipid efflux translo-
cator and a positive regulator of biliary lipid secretion, acting as a
phospholipid flippase which translocates phosphatidylcholine (PC)
from liver hepatocytes into bile, thus being essential for bile formation.
It can also influence the composition of lipids of the plasma membrane,
recruiting PC, phosphatidylethanolamine (PE) and sphingomyelin (SM)
towards non-raft membrane domain or contributing to cholesterol and
SM-enrichment in raft membranes in hepatocytes (Morita and Terada,
2014). ABCB4 cooperates with ATP8B1 to protect hepatocytes from the
detergent activity of bile salts (Groen et al., 2011).
ABCB4 and ABCB1 belong to ABC transporters superfamily, and are
encoded by fused genes, arising from an endoduplication event, and
often co-amplified because of their genomic proximity (about 500 Kb);
they share 80% nucleotide sequence identity, and 77% identity and
82% similarity in the amino acidic sequence (Callen et al., 1987;
Torigoe et al., 1995; Van der Bliek et al., 1987; Van der Bliek et al.,
1988).
ABCB4 is well expressed in the liver; its substrates are PC and some
hydrophobic drugs, while in MDR cells ABCB4 is particularly selective
for paclitaxel and vinblastine (Gottesman et al., 2002; Thomas and
Coley, 2003). ABCB4 is co-amplified with ABCB1 in several MDR cancer
cell lines. In doxorubicin-resistant colon cancer cell lines, its mRNA is
up-regulated up to 40-fold compared to parental cell lines, and this
amplification is possibly due to the concomitant amplification of the
ABCB1 gene (Chao et al., 1991). A dose-dependent increase in ABCB1
and ABCB4 levels is observed in doxorubicin-, paclitaxel- and vincris-
tine-resistant cancer cell lines upon drug selection; further, in some of
these tumor cell lines, up-regulation of ABCB4 was higher than that of
ABCB1, suggesting a compensatory mechanism in drug resistance when
ABCB1 is not overexpressed, and an active role for ABCB4 in MDR,
driven preferentially towards doxorubicin and paclitaxel (Januchowski
et al., 2017; Januchowski et al., 2014a; Januchowski et al., 2014b).
The increased mRNA and protein levels of ABCB4 along with those
of ABCB1 in acquired paclitaxel-resistant breast cancer cells highlights
a role of ABCB4 in taxane resistance, since it was shown that directed
siRNA silencing towards ABCB1 did not restore the complete paclitaxel
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sensitivity in these cancer cell lines co-overexpressing both ABCB1 and
ABCB4 (Nemcova-Furstova et al., 2016). This matter is still conflicting,
as while ABCB4 silencing in paclitaxel-resistant ovarian cancer cells
does not fully restore drug sensitivity, ABCB1 silencing completely re-
verses MDR (Duan et al., 2004a). However, it seems that transcriptional
regulation of ABCB4 gene expression relies mostly on ABCB1 co-am-
plification; nevertheless, ABCB4 has a role in drug resistance, pre-
ferentially in taxanes, hence complementing the protective role of
ABCB1 against various MDR type anticancer drugs
CROT
Carnitine O-octanoyltrasferase is a peroxisomal protein that plays a
role in lipid metabolism and fatty-acid beta-oxidation. DNA copy in-
crease and increased expression of CROT, together with that of other
proteins of the 7q21.11-13 chromosomal region, was observed upon
progressive administration of paclitaxel and docetaxel to 18 ovarian
cancer cell lines (Wang et al., 2006), and of docetaxel to the MCF-7
breast cancer cell line (Hansen et al., 2016). MiR-33 co-downregulates
the expression of ABC transporters and CROT (Fernandez-Hernando
et al., 2011).
TP53TG1 lncRNA
TP53TG1 is a p53-induced lncRNA, which is activated upon DNA
damage and acts as a tumor suppressor, contributing to p53 response to
DNA damage (Diaz-Lagares et al., 2016). It was reported to bind YBX1
DNA/RNA binding protein, preventing its nuclear localization and
subsequent activation of oncogenes (Diaz-Lagares et al., 2016). The first
evidence of its down-regulation came from microarray experiments
performed on A549 cisplatin-resistant lung cancer cell lines (Yang et al.,
2013). In colorectal cancer cells the TP53TG1 promoter undergoes a
hypermethylation that causes the release of the YBX1 protein and
subsequent transcription of oncogenes, resulting in an MDR phenotype
(Lizarbe et al., 2017). The same findings were reported by Diaz-Lagares
and coworkers in other cancer cell lines (Diaz-Lagares et al., 2016).
Beside the epigenetic inactivation of TP53TG1 transcription, its
upregulation has been reported in T lymphocytes exposed to ionizing
radiations, in colon cancer cells treated with bleomycin or cisplatin and
in docetaxel-resistant breast cancer cells (Hansen et al., 2016; Kabacik
et al., 2015; Takei et al., 1998). TP53TG1 is the first lncRNA activated
upon induction of double strand breaks (DSBs), confirming its activa-
tion upon cell stress and DNA damage (Kabacik et al., 2015). Ad-
ditionally, overexpression of TP53TG1 has been observed in glioma
cells, compared to normal brain tissue. This up-regulation results in cell
proliferation and migration, especially under glucose deprivation (Chen
et al., 2017). Cellular TP53TG1 lncRNA expression is up-regulated
under stress conditions (and in docetaxel-resistant breast cancer cells),
but its promoter can be epigenetically silenced in cancer cells leading to
the development of MDR, suggesting a role in the development of in-
trinsic MDR.
TMEM243 (MM-TRAG, or MGC4175)
TMEM243 (MDR1- and mitochondrial taxol resistance-associated
protein transmembrane protein 243) is a transmembrane protein that
localizes at nuclei, mitochondria and cell membrane; it is expressed in
all tissues with no reported differences between normal tissues and
chemotherapy naïve cancer cells (Duan et al., 2004b), and is over-
expressed in taxane-resistant ovarian cancer cells (Wang et al., 2006), a
possible indication of a role in acquired MDR.
Microarray experiments reported an up-regulation in taxol- and
doxorubicin-resistant cancer cell lines, compared to the non-treated
cancer cells. Under these conditions, TMEM243 is present as a single
copy gene, and its overexpression is not due to genomic amplification
or gene rearrangements (Duan et al., 2004b), suggesting a mechanism
of acquired MDR. Furthermore its expression has been reported as as-
sociated with paclitaxel resistance in drug-resistant breast cancer cells
(Dorman et al., 2016) and in doxorubicin-resistant osteosarcoma cell
lines, where microarray and qPCR experiments showed a 2-fold upre-
gulation (Rajkumar and Yamuna, 2008).
DMTF1 (DMP1)
DMTF1 (Cyclin-D binding myb-like transcription factor 1) is a
transcriptional activator of CDN2A/ARF locus in response to RAS-RAF
signaling promoting cell growth arrest p53-mediated. It binds to ARF
activating its transcription and stimulating p53 quenching with onco-
genic signaling pathways (RAS, HER2neu, C-MYC, cyclin D), thus
acting as an oncosuppressor (Frazier et al., 2012; Fry et al., 2016).
DMTF1 contains a cyclin D-binding domain, three central myb or myb-
like domains, and two flanking acidic transactivation domains. The
structure of the N-terminal, myb-like domain of DMTF1 has been solved
by NMR (PDB accession code: 2LLK). In DMTF1, myb-like domains are
able to bind both DNA and proteins. DMTF1 physically interacts with
p53, preventing its ubiquitination by Mdm2, thus promoting nuclear
localization of p53 (Frazier et al., 2012; Kendig et al., 2017). DMTF1 is
highly expressed in terminally differentiated cells and experimental
evidence showed that in hematopoietic cell lines, its repression oc-
curred by WT1, which is expressed only in hematopoietic progenitors,
thereby leading to leukemia (Tschan et al., 2008). Furthermore DMTF1
mRNA is decreased in AML cell lines compared to normal granulocytes
and treatment with ATRA restored normal levels of the DMTF1 tran-
script (Inoue and Fry, 2016).
Van Dekken and collaborators reported a high level of amplification
of genes residing on the 7q chromosome region in adenocarcinoma of
the gastroesophageal junction, including DMTF1 (van Dekken et al.,
2006). Acquisition of docetaxel resistance in breast cancer cells corre-
lates with overexpression of DMTF1, together with that of other pro-
teins of the ABCB1 amplicon (Hansen et al., 2016). On the other hand,
the human DMTF1 gene appears to be deleted in 40% of human non-
small-cell lung carcinoma (NSCLC), that generally have normal levels of
ARF and p53 (Sugiyama et al., 2008); corroborating results reported
that DMTF1 deletion in breast cancer cell lines brings about features of
tumor aggressiveness renders p53 inactive (Fry et al., 2017). In addi-
tion, DMTF1 transcription is repressed upon anthracycline treatment,
thus leading to NF-kappaB-dependent repression of the Arf-p53
pathway; both DMTF1(-/-) and ARF(-/-) cells are anthracycline-re-
sistant (Taneja et al., 2007).
Other researchers reported that DMTF1 deletion cooperates with
kRAS signaling for the development of cancer in vivo, and confirmed
that it acts as a primary regulator of lung carcinogenesis, being a reg-
ulator of ARF-p53 pathway (Mallakin et al., 2007).
It has been observed that this deletion brings a consequent loss of
DMTF1 and leads to tumorigenesis in a mouse model as well; it has been
noted that DMTF1(+/−) mice, harboring a copy of the gene, still de-
veloped tumors, suggesting a DMTF1 haploinsufficiency (Inoue et al.,
2007). The hemizygous copy of DMTF1 gene is found at high frequency
in breast cancer cells (Maglic et al., 2015), undergoing a fine post-
transcriptional regulation. Indeed its mRNA is alternatively spliced to
three variants (α,β,γ) that can exert different functions (Inoue and Fry,
2016). DMTF1γ has an unknown function, but interestingly α and β
variants have two divergent functions; in breast cancer, the α variant is
p53-dependent and acts as a tumor suppressor, whereas the β variant is
p53-independent and acts as an oncogene. Furthermore, DMTF1 β/α
ratio increases with neoplastic transformation, and high β variant ex-
pression is associated with a shorter survival rate in cancer. DMTF1β
was also found overexpressed in primary breast cancer, with a negative
impact on patients survival, and it does not activate ARF, suggesting
that the β variant may antagonize α’s dependent ARF activation,
leading to cell proliferation and tumorigenesis (Inoue and Fry, 2016).
Alternative splicing of DMTF1 transcript is a way for cancer cells to
modulate survival and proliferation since it has been observed that 30%
of breast cancer cells have higher amounts of β rather than α, and that
the β mRNA is 43–55% higher in breast cancer while the β protein is
increased by 60% in tumors, suggesting a fine post-transcriptional
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regulation (Maglic et al., 2015). The DMTF1β variant can be thus
considered a cancer biomarker, and proteins that activate the DMTF1
promoter or stabilize the DMTF1α variant, lead to regression of tumor
growth in vitro (Fry et al., 2017).
Another strategy of post-transcriptional regulation of the DMTF1
gene is exerted by miR-155, an oncogenic microRNA. In bladder cancer
tissues miR-155 reduces the expression of DMTF1, leading to cell cycle
progression and enhancement of cancer cell growth (Peng et al., 2015).
DMTF1 expression regulation in cancer mainly relies on gene de-
letion, since it is generally considered as a haploinsufficient tumor
suppressor, and also on post-transcriptional regulation that leads to its
down-regulation, even though alternative splicing plays an intriguing
role in the up-regulation of the oncogenic DMTF1 variant (Inoue and
Fry, 2016).
Future perspectives
The idea of ABCB1 as a major player in MDR is now outdated, and 4
generations of ABCB1 transport inhibitors have been unexpectedly and
disappointingly ineffective in the clinic. Emerging contributions to
MDR in tumors continue to increase, and resistance to chemother-
apeutic drugs is now considered a complicated puzzle, with an ever-
increasing number of pieces, involved in many different functions, with
complex and intricate connections, acting at multiple regulatory levels.
Even at the single level of ABCB1 expression, the co-amplification and/
or co-expression of genes of chromosome 7q21 residing on the same
amplicon is emerging as a factor that contributes and modulates MDR.
The contribution of TP53TG1 lncRNA, TMEM243, SLC25A40,
RUNDC3B, ADAM22, and in particular of SRI, ABCB4, DMTF1 and DBF4
is now acknowledged as an important determinant of MDR.
Deciphering their functions could pave the way for the development of
novel clinically relevant strategies for therapeutic interventions in
cancer. In addition, gene-targeting and expression modulation strate-
gies, e.g. by the use of epigenetic drugs, non-coding RNAs or natural
products can represent possible options, both for the improvement of
the knowledge of the molecular basis of MDR and for drug discovery.
CDC7-DBF4 inhibitors are already available and are considered good
potential anti-tumor drug candidates: PHA-767491 and XL413 are se-
lective inhibitors, with good antitumor activity vs. several tumors, such
as glioblastoma, pancreatic cancer, colon and breast cancer
(Erbayraktar et al., 2016; Montagnoli et al., 2008; Natoni et al., 2011;
Sasi et al., 2017). The use of combined administration of drugs tar-
geting ABCB1, Sorcin and CDC7-DBF4 could prove a viable and more
effective therapeutic strategy against MDR tumors.
Conclusions
MDR continues to pose a dominant obstacle towards curative che-
motherapy against various human cancers. ATP-driven efflux pumps,
ABCB1 in particular, are responsible for drug expulsion and have a
significant role in conferring MDR upon various cancer cells, that de-
velop cross-resistance to diverse anticancer drugs, resulting in the
failure of chemotherapy in multiple malignancies (Ambudkar et al.,
1999; Fletcher et al., 2016; Holohan et al., 2013; Li et al., 2016b;
Sharom, 2011; Silva et al., 2015). Overexpression of ABCB1 in tumors,
particularly upon chemotherapeutic treatment, is possibly the major
cause of treatment failure; notwithstanding the design of 4 generations
of ABCB1 transport inhibitors and the wealth of information on the
biochemistry and substrate specificity of ABC transporters, translation
of this knowledge from the bench to the bedside has proved to be un-
expectedly difficult.
Many studies have shown that upon repeated treatment of cultured
tumor cell lines with a plethora of anticancer drugs including for ex-
ample taxenes, anthracyclines, Vinca alkaloids, epipodophyllotoxins
and other chemotherapeutic drugs, amplification, and/or over-
expression of a series of genes surrounding the genomic ABCB1 locus is
observed; altered levels of these proteins may correlate with the es-
tablishment of the MDR phenotype, and lead to poor clinical outcome.
Genes in the ABCB1 amplicon (with the exception of the tumor sup-
pressor TP53TG1 lncRNA) were generally up-regulated in many can-
cers, and especially in MDR tumors; all of these genes are directly in-
volved in tumor growth and drug resistance and finely regulated in
various modes, from canonical transcriptional upregulation to epige-
netic and post-transcriptional control.
The genes in the ABCB1 amplicon exert important roles for cell
survival in cancer or MDR status, as p53-mediators of cell growth arrest
(TP53TG1 and DMTF1), cell cycle or cell proliferation regulators (DBF4
and ADAM22), mediators of signaling pathways (RUNDC3B), mi-
tochondrial transmembrane proteins (SLC25A40 and TMEM243), ATP-
driven pumps (ABCB4) or calcium and xenobiotic sensors (Sorcin). In
particular, Sorcin is able to limit the cytotoxic activity of chemother-
apeutic agents in tumor cells and to confer MDR via three known me-
chanisms: by direct binding to chemotherapeutic drugs as well as its
overexpression on the one hand induces ABCB1 overexpression and on
the other hand activates pathways leading to EMT and metastasis.
In conclusion, the gain of knowledge about these genes and their
role in cancer and chemoresistance can possibly pave the way towards
the development of novel biomarkers as well as offer important in-
formation on tumorigenesis and MDR mechanisms. A possible strategy
to overcome MDR in cancer could be by considering the targeting of
these proteins, which are often co-overexpressed along with ABCB1 in
MDR tumors, and can be used as biomarkers of poor cancer patient
outcome.
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